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Staphylococcus aureus is a significant cause of morbidity and mortality world-
wide.  This opportunistic pathogen is capable of causing several severe diseases that are 
exacerbated by its diverse and widespread antibiotic resistance profile. Therefore it is 
necessary to identify novel therapeutic targets to effectively treat S. aureus disease. Lorenz 
et al first described the Immunodominant Surface Antigen B, IsaB, because it was 1 of 4 
unique proteins immunogenic during septicemia and not colonization, suggesting that IsaB 
may be a virulence factor and a possible novel therapeutic target.  Interestingly, IsaB has 
no homology to proteins of known function and appears to be found only in Staphylococci.  
We sought to characterize the function of IsaB in S. aureus.  We began our studies by 
   
 xvi 
determining how isaB was regulated by known S. aureus regulators and environmental 
stimuli.  It was observed that the transcriptional regulator SarA represses expression of 
isaB, while serum and acidic pH induce expression. We found that IsaB is an extracellular 
nucleic acid binding protein, able to bind to dsDNA, ssDNA, and RNA and leads 
significant accumulation of eDNA on the cell surface.  We employed multiple virulence 
models to ascertain the role of IsaB in virulence.  Excitingly, we found that IsaB 
significantly protects S. aureus from antimicrobial peptides and Neutrophil Extracellular 
Traps, both components of the innate immune system.   Another virulence mechanism of S. 
aureus is the ability to form biofilms.  While recent studies show a significant role for 
eDNA in S. aureus biofilms, we found that IsaB actually had a negative affect on biofilms 
under certain growth conditions.  Finally, to group IsaB into a known functional class, we 
successfully expressed and purified mature IsaB for structural determination by Nuclear 
Magnetic Resonance, which is currently underway.  Our studies show that IsaB is a novel 
virulence factor of S. aureus, able to bind eDNA and significantly protect from AMPs and 
NETs, and could therefore play a key role in immune evasion.    
 
  1 
 
 
 
 
CHAPTER 1 
Introduction  
 
 
 
 Clinical relevance of S. aureus 
 Staphylococcus aureus is a potent opportunistic pathogen, causing significant 
morbidity and mortality on a global scale and is the leading cause of nosocomial infections 
in the United States. The genus Staphylococcus is made up of over 40 species, most of 
which are not significant contributors to human disease [1].  S. aureus is the headlining 
member of the genus due to its imposing ability to cause a variety of potentially life-
threatening human diseases.  The staphylococci are non-motile, facultative anaerobic 
Gram-positive cocci.  All staphylococci possess catalase, however only S. aureus produces 
coagulase, which is the standard marker used to differentiate S. aureus from other 
Staphylococcus species.  The genus name comes from the Greek word staphyle, for the 
grape-like cluster morphology observed upon Gram-staining the organism. The species 
name comes from the Latin word aurum, gold, for its golden colony pigmentation which is 
due to the presence of staphyloxanthin [2].  
While S. aureus is an important human pathogen, it is also capable of colonizing 
30-50% of the population either permanently or transiently [3, 4].  An important distinction 
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between colonization and infection is that during colonization, unlike infection, the host is 
not adversely affected, and oftentimes there is only a very acute local immune response if 
any is observed at all [5, 6]. S. aureus can be found on moist areas of the skin (interior of 
elbows and armpits), however, colonization most often occurs in either the anterior nares 
or the back of the throat [3, 4].  While colonization is not likely to harm a healthy 
individual, it is a risk factor for disease once normal protective barriers or defenses are 
weakened.  Carriers who become infected with S. aureus are usually infected with their 
own resident strain. 
Once S. aureus crosses the epithelial boundary, it can cause a large number of 
disease manifestations with varying degrees of severity.  S. aureus is the leading cause of 
purulent soft tissue infections, causing folliculitis, impetigo and carbuncles (boils). These 
disease manifestations are generally self-limiting and not severe [7, 8].  However, S. 
aureus is also a leading cause of a wide variety of life-threatening infections such as 
osteomyelitis, and infective endocarditis, which are chronic infections of bone tissue and 
heart valves, respectively [7, 8].  S. aureus is also capable of causing both necrotizing 
pneumonia and fasciitis, as well as toxinoses such as toxic shock syndrome, all of which 
are often fatal.   
Due to severity of disease caused by S. aureus, it is essential to start effective 
antibiotic intervention immediately.  Antibiotic choice is complicated by diverse 
mechanisms of resistance and the widespread presence of methicillin resistant S. aureus 
strains (MRSA) [9].  Until recently MRSA was thought to be a significant threat only in the 
hospital setting, as S. aureus is the leading cause of nosocomial infections [9, 10].  
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However, it has been shown that normal healthy individuals are becoming infected with 
community acquired MRSA strains, CA-MRSA, which are thought to have evolved 
separately from HA-MRSA, and are frequently hypervirulent [9, 11, 12].  
While oxacillin (clinically-approved form of methicillin) is the drug of choice 
against S. aureus, it is ineffective against MRSA, therefore alternate antibiotic 
interventions must be employed immediately upon confirmation of MRSA in order to stop 
disease progression before S. aureus overwhelms the host defenses and causes death.  It is 
important to note that S. aureus is inherently susceptible to a number of other drugs such as 
erythromycin and tetracycline, however the chromosomal cassette carrying the mecA 
methicillin resistance gene also contains genes that confer resistance to many of these other 
antibiotics [13].  Two antibiotics that are used clinically to treat MRSA are vancomycin 
and daptomycin [13-15].  These second line antibiotics are used sparingly so as not to 
promote the spread of resistant strains, which have been clinically documented, especially 
for vancomycin intermediate resistant (VISA) and vancomycin resistant S. aureus (VRSA) 
[13, 14, 16].  Due to the continuously rising prevalence of strains resistant to all relevant 
antibiotics, there has been a strong push from clinicians and scientists to find other 
effective treatment modalities. In order to find therapeutic targets, it is essential to 
understand the pathogenesis and virulence factors of this organism. 
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Virulence factors 
Immune Evasion and Virulence 
Neutrophils.  While S. aureus is, on occasion, able to subvert the host 
barriers and the immune system in order to cause disease, host defenses are usually capable 
of eradicating S. aureus before establishment of infection begins. Neutrophils are the 
body’s primary defense against S. aureus [2, 17, 18].  Thus, neutrophils are extremely well 
adapted and equipped to thwart these invaders.  Neutrophils can kill by a number of 
different mechanisms: releasing granules full of peroxide as well as antimicrobial proteins 
and peptides, by production of ROSs through an oxidative burst, and their calling-card 
method, phagocytosis/opsonophagocytosis [2, 17-19].  Not surprisingly, S. aureus is 
similarly well equipped to take on neutrophils and knock them out.  Some examples of 
proteins that S. aureus use to avoid killing by neutrophils are: chemotaxis inhibitory 
proteins of Staph (CHIPs), which prevents neutrophil recruitment, and Panton Valentine 
Leukocidin (PVL), which is a pore forming leukotoxin [17, 18, 20-23].  
Opsonophagocytosis.  While neutrophils are potent killers, their innate 
activity is greatly enhanced in a process known as opsonization.  Opsonization is the 
process in which complement, a major antimicrobial component of serum, and pathogen 
specific antibodies, are deposited on the bacterial cell surface.  Opsonization kick-starts a 
dramatic antibacterial sequence of events in a number of ways.  When complement binds 
to the bacterial cell surface it becomes activated through proteolysis that releases a number 
of factors, which actively recruit chemotactic cells, including neutrophils, to the site of 
intrusion [17, 18, 24].   
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Once the neutrophils arrive on scene they recognize and bind to either the Fc 
portion of specific antibodies bound to the bacterial cell with Fc receptors, or they can bind 
to the deposited complement (c3b) via CR1 [17, 18, 24, 25].  Binding of either ligand to its 
receptor induces phagocytic pathways ending with the bacteria being internalized within a 
phagolysosome that efficiently destroys the bacteria [17, 18].  However, S. aureus has 
ways to inhibit this process at a number of points, including the inactivation of 
complement by Staphylococcal Complement Inhibitor (SCIN), evasion of opsonization by 
binding to host fibrinogen via CflA, and also by binding the Fc regions of antibodies which 
is one function of Protein A [2, 17-19, 25]. 
 Antimicrobial peptides. Antimicrobial peptides, AMPs, are another 
important arm of innate immunity that target and kill S. aureus.  These small cationic 
peptides, which are found in virtually all higher organisms, have recently become attractive 
drug candidates, due their natural production in and protection of many host tissues and 
cell types [26-28]. AMPs are highly effective against most bacteria, regardless of Gram-
type, because the overall external charge on the bacterial envelope is negative, which 
differentiates them from self, as eukaryotic cells are typically “seen” as neutral [27, 28].  
Interestingly, production of AMPs is not exclusive to the typical immune cells (i.e. 
neutrophils), they are produced by numerous cell/tissues types, most notably epithelial 
cells in the skin and lungs, and also by the cells of the gastrointestinal tract [27, 29, 30].  
While S. aureus is susceptible to a number of AMPs, it has evolved mechanisms of 
defense, proteins and systems associated with protection from these bactericidal AMPs 
[26, 29-34].  AMPs act by binding to the bacterial membrane via charge interactions and 
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can form pores in the membrane, they can activate hydrolases or autolysins, and can even 
be internalized and disrupt cellular processes [27, 32, 35, 36].  Therefore, most S. aureus 
resistance strategies involve alteration of the overall charge of the cell wall, proteolysis, as 
well as active transporter systems [26, 31, 32, 34].  A few of the genes that have been 
associated with AMP resistance are: mprF, which encodes a membrane protein involved in 
membrane modification, dlt operon whose gene products are required for efficient D-
alanylation of teichoic acid which inhibits autolysin activity, and finally graRS, a two-
component system [26, 31, 32, 35]. 
 
Adhesion and Invasion 
Along with the virulence factors involved in immune evasion, S. aureus also has a 
diverse array of other factors that allow for adherence to host tissues.  MSCRAMMs, 
microbial surface components recognizing adhesive matrix molecules, and SERAMS, 
secretable expanded repertoire of adhesive molecules, are critical for the initiation of 
disease as these proteins are responsible for S. aureus binding intimately to host tissues 
[37].  MSCRAMMs and SERAMs are protein families with multiple members that allow 
for binding to host fibrinogen, fibronectin, elastin, collagen, vitronectin, β-neurexin, and 
cytokeratin 10 [37-43].  Furthermore, S. aureus deficient in many of these proteins, 
including SdrC, FnBPA, FnBPB, and Eap have been shown to significantly decreased 
adherence to various human cell lines [37, 38, 41].   
In concert with adherence, recent studies have shown that S. aureus can invade and 
survive intracellularly in both phagocytic and non-professional phagocytic cells [42, 44-
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49].  One process by which S. aureus can be actively internalized is through fibronectin 
binding proteins interacting with receptors on the host cell surface, initiating uptake of the 
bound bacteria [37, 44].  The invasive strategy is likely a process to avoid innate and 
cellular host defenses, as once inside cells they are protected from professional phagocytes 
and also from AMPs, antibodies and complement.  Recently a study by Zautner et al, have 
demonstrated that intracellular S. aureus is responsible for a large proportion of recurring 
tonsillitis infections [50].  Due to the amount of resources and proteins committed to 
promoting adherence and even invasion in to host-tissues, it easy to see how important 
these strategies are to the pathogenesis of S. aureus within the host. 
 
Biofilm formation  
 Biofilms are sessile multi-cellular communities of bacteria that are encased in an 
exopolymeric substance [51, 52].  Many environmental and pathogenic bacteria have been 
found to form biofilms, either in the environment or within a host during infection [52].  
The biofilm growth phenotype is now thought to be the default mode of growth for 
bacteria, insomuch as approximately 75% of infections are biofilm related [51].  Biofilms 
are likely preferred because this growth phenotype confers increased survival of the 
bacteria under many stressful conditions such as low nutrient availability, presence of 
antibiotics, phagocytes, and both oxidative and shear stresses [53].  
S. aureus biofilms are clinically relevant as they have been found to be essential in 
the pathogenesis of a number of chronic infections such as catheter infections, infections of 
indwelling medical devices, chronic rhinosinusitis [54-58].  While S. aureus infections can 
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be difficult to treat as a result of antibiotic resistance determinants, the chronic biofilm 
diseases are even more so, and often require the removal of the infected device or surgical 
debridement of infected tissues.  Part of the difficulty of treating biofilms is due to the fact 
that biofilms are intrinsically up to a 1,000X more resistant to antibiotics.  Also 
compounding treatment and causing recurring infections is the presence of persister cells 
which can re-colonize a bacterial biofilm after antibiotics are removed, thus re-initiating 
infection [51, 59]. 
Biofilm formation is a multi step process relying first on attachment to a surface, 
followed by secretion of an exopolymeric substance (EPS) which leads to irreversible 
attachment, and finally outgrowth and maturation of the biofilm structure [51, 60, 61].  An 
important EPS of the S. aureus biofilm matrix component is the exopolysaccharide poly-
N-acetylglucosamine, PNAG, which is encoded by the intracellular adhesin locus, ica [61-
63].  However several recent studies have found that both extracelluar DNA (eDNA) and 
several surface proteins, such as the SERAM Eap, can play a more significant role in 
biofilm formation than PNAG under certain conditions [61, 62, 64-67].  Furthermore, a 
number of transcriptional regulators have been found to be important in biofilm formation, 
for example SarA, which is considered a major regulator, is capable of regulating biofilm 
formation in both ica dependent and independent mechanisms [63].  While much is now 
known about S. aureus biofilm formation, the production and regulation of biofilms is a 
very active topic of study and it is likely that many novel biofilm associated factors and 
mechanisms will be described in the near future. 
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Regulation of virulence 
S. aureus not only needs to control its normal cellular functions involved in 
metabolism and growth, it also must have efficient ways to respond quickly to an infinite 
number of environmental stimuli. This network is further expanded once you take into 
account the myriad of environmental information it must respond to, such as antibiotics, 
phagocytes, antimicrobial peptides, complement, etc. In response to these signals S. aureus 
is able to regulate its plethora of virulence factors in a manner that is specific and 
appropriate for the current stage of infection.  To accomplish this large feat, S. aureus has 
multiple regulatory mechanisms involving 3 sigma factors, 16 two-component systems, a 
quorum sensing system through the Agr/RNAIII pathway, and a large repository of 
transcriptional regulators [68-70].  While hundreds of reviews on S. aureus regulation have 
been published, for the purposes of this report we will focus on two “global” regulators, 
SarA and CcpA, both of which have been implicated in virulence, metabolism, and biofilm 
formation. 
Staphylococcal accessory regulator A. The Staphylococcal accessory 
regulator A, SarA is the prototype for the 11-member Sar family of DNA binding 
regulators that S. aureus uses to respond to changing local environments [71].  SarA is a 
DNA binding protein which is known to regulate the expression of many virulence factors, 
especially extracellular proteases, cell wall proteins and biofilm formation [72-75].  Active 
SarA forms a homo-dimer which results in a winged helix motif, allowing for DNA 
binding to occur by both the winged and helix-turn-helix motifs, which interact with the 
minor and major grooves, respectively [71, 76].  It is also been shown that SarA binds to 
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the promoter regions of its targets by recognizing a specific consensus sequence.  A 
number of studies have been performed by various labs to characterize and predict the 
SarA consensus sequence, which can be a helpful tool for determining a direct or indirect 
SarA regulatory effects [75, 77].  Importantly, SarA has been found to both positively and 
negatively regulate factors depending on how it interacts with the targeted promoter; it can 
bend DNA in such a way that it is either optimal or inhibitory for transcription to occur 
[71]. 
Expression of SarA is dependent upon growth phase, with its greatest expression 
observed during the late exponential growth phase [15].  Thus, it can regulate virulence 
determinants in a temporal manner.  Interestingly, SarA has been found to be both a 
positive and negative regulator of different virulence factors and its regulatory effects can 
be predicted by protein class.  SarA has been consistently found to repress expression of 
extracellular proteases while positively regulating expression of proteins involved in 
biofilm formation and cell wall-associated proteins [15-18].  One can surmise that SarA is 
turned on when cells are at a high enough density where adherence to tissues is desired, 
and where extracellular proteases can be detrimental, possibly by eliciting an immune 
response.  Furthermore, SarA has been found to play a significant role in the regulation of 
biofilm formation and also of both the agr locus and RNAIII, which constitute the main 
components of the quorum sensing system [63, 71]. 
Carbon Catabolite Protein A.  S. aureus metabolism is a highly regulated 
and tightly orchestrated activity that allows S. aureus to efficiently use every energy source 
it can.  During aerobic growth and in the presence of simple sugars (glucose, fructose, 
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sucrose, etc) S. aureus will begin metabolism through Embden-Meyerof-Parna pathway, 
commonly referred to a glycolysis [69].  Glycolysis is only the first step in aerobic 
metabolism in S. aureus, which can also utilize the TCA and pentose phosphate pathways.  
The TCA cycle typically takes over during the transition to exponential phase once the 
available supply of glucose has been extinguished.  Importantly, during glycolysis there is 
a build-up of by-products, one of which is acetic acid.  Aside from causing a drastic 
decrease in pH, acetic acid can be used as an acetate source which is an important 
metabolic substrate of the TCA cycle [69].   
So in rich media, where many potential carbon sources available, how does S. 
aureus choose what it would like to “eat”?  Metabolism is like a popularity contest where 
available carbon sources (i.e. sugars) compete for favor, with the prom-queen, glucose, 
ultimately beating out other contestants.  Not only does glucose trump the other 
contestants/sugars, it starts a regulatory system that will shut-down genes useful for 
metabolism of other carbon sources, while turning on genes for its metabolism as well as 
other factors [78-81].  Glucose’s handy-man is the Carbon Catabolite Protein A, CcpA, 
which is a global regulator in S. aureus and has homologues in most other bacteria.  CcpA, 
along with its partner HPr, is responsible for carbon catabolite repression (CCR) in a 
number of low GC content Gram-positive bacteria, such as B. subtilis (in which CCR has 
been extensively studied), B. cereus, L. lactis, S. mutans, S. pyogenes, S. epidermidis and 
S. xylosus [69, 78, 80, 82, 83].  
CcpA, binds to DNA promoter regions called CREs (catabolite-responsive 
elements), and becomes “activated” when its co-factor, HPr is phosphorylated, which 
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occurs through the sensing of glucose intermediates [69, 84].  Interestingly, the level of 
CcpA stays at a constant level in the cell and is not expressed in response to glucose [69].  
While CcpA is typically thought of as a repressor, it can act as both a repressor and an 
activator depending on where/how the active CcpA/P-ser-HPr complex binds to promoters 
[69, 78, 84-87].  CcpA has also been found to have significant roles in regulating virulence 
factors such as hla, and spa [86].  Furthermore, a role for CcpA has been implicated in 
biofilm formation as a CcpA deficient strain exhibited decreased ability to form biofilms 
[86].  While CcpA has been studied exhaustively in B. subtilis, only a few published 
reports have looked into the CcpA regulon and activity in S. aureus, and it will be 
interesting to see the extent of its role in virulence. 
 
The Immunodominant surface antigen B (IsaB)  
A study by Lorenz et al, investigated the antibody response of patients who 
recovered from MRSA septicemia in an effort to identify possible targets for antibody 
therapy [88].  In their study, they compared the antibody response at the onset of MRSA 
septicemia to the one observed during convalescence.  Screening pre- and post-infection 
serum against nine clinical MRSA strains they found that upon patient recovery, at least 
four distinct proteins had induced an immune response; and the authors hypothesized that 
these antibodies would be protective.  They designated one of the four proteins as 
Immunodominant surface antigen B (IsaB), a 17kDa S. aureus protein with no significant 
homology to other proteins with known function.  While all septic patient sera tested 
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contained antibodies towards IsaB, sera collected from healthy or healthy-colonized 
individuals had little or no antibody reactivity against IsaB.   
The findings that IsaB antibodies are absent in individuals who have not experienced a S. 
aureus infection but present in individuals who have recovered from septicemia suggest 
that IsaB is immunogenic during acute infection. This also suggests that IsaB is expressed 
during infection and may indicate that it is a virulence factor of S. aureus.  The 
identification of novel virulence factors, in particular those that elicit a robust immune 
response, could lead to new therapeutic agents to combat this important pathogen.  
Our goal therefore was to characterize the regulation, structure, and function of 
IsaB, as well as its role in virulence.  From these studies we have identified a number of 
external and internal factors involved in the regulation of isaB expression.  We found that 
IsaB is a nucleic acid-binding protein and used Electro-mobility shift assays (EMSAs) and 
surface plasmon resonance (SPR) to elucidate and characterize its affinity for RNA and 
DNA.  We investigated role of IsaB in virulence, immune evasion, and biofilm formation, 
and found that IsaB is protective against both AMPs and NETs.  Finally, we characterized 
the structure of IsaB by nuclear magnetic resonance.  
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CHAPTER 2 
Methods and Materials  
 
 
Strains and growth conditions  
Bacterial strains used in these studies are listed in Table 1.  S. aureus strains were grown 
on Tryptic Soy Agar plates (TSA) ( BD, Sparks, Md ), or TSA plates supplemented with 
(10µg/ml) erythromycin (erm) as required for selection at 37℃ overnight, or as indicated.  
Liquid cultures of S. aureus were grown in either Tryptic Soy Broth (TSB)(EMD 
Chemicals Inc, Gibbstown, NJ) or Luria Bertani Broth (LB)(EMD Chemicals Inc), with or 
without supplementation of 1% D-Glucose (TSBG or LBG) (Fisher Scientific, Fair Lawns, 
NJ) at 37℃ overnight with shaking at 200 rpm.  E. coli strains were grown in LB, either 
broth or plates, supplemented with (100µg/ml) ampicillin, (35µg/ml) chloramphenicol, or 
(50µg/ml) kanamycin as required for antibiotic selection, at 37℃ overnight.  Primers used 
throughout these studies are listed in Table 2. 
 
RNA Extraction 
Samples were separated by centrifugation at 25℃, the spent media was discarded and 
pellets were frozen immediately at -80℃ until use.  The Qiagen RNeasy® mini kit  
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Table 1.  Bacterial Strains Used. 
Strain Species Resistance 
10833 S. aureus  
10833ΔisaB S. aureus Erm 
10833ΔnPase S. aureus Erm 
10833ΔtagO S. aureus Erm 
Sa113 S. aureus  
Sa113ΔisaB S. aureus Erm 
Sa113ΔsarA S. aureus Erm 
Sa113ΔccpA S. aureus Erm 
RN450 S. aureus  
502 S. aureus  
502ΔsrtB S. aureus Erm 
Top10 E. coli  
BL21-pLYS(DE3)-pRIL E. coli Cm 
Op50 E. coli  
BL21-pLysS(DE3)-pRIL + isaB E. coli Cm, Kan 
BL21-pLysS(DE3)-pRIL + m-isaB E. coli Cm, Amp 
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Table 2. Primers and Oligos. 
Name Sequence 
WTUTR-c 5’-BIOTIN-TGCaauuacaaauauuuccguuuaauuauaacaacaaucuauuGCA-3’ 
IsaBIntein 5’-GGGCATATGAATAAAACCAGTAAAGTTTGTGTAGC-3’ 
IsaBInteinREV 5’-GGTTGCTCTTCCGCAACCTTTACTTGTTTTGTATGGTGTATGTCC-3’ 
isaBXhoFWD 5’- GGGCATATGGTTTGTGTAGCAGCAACATTAGC-3’ 
isaBXhoREV 5’-GGGCTCGAGCGAAGTAACAGTTGGACATACACC-3’ 
icaUTR6 5’-GUUUAAUUAUAACAACAAUCUAUUGCA-3’ 
BioticaPRO 5’-BIOTIN-ATTGVGTTATCAATAATCTTA-3’ 
IcaRcloneFWD 5’-GGTGGGATCCTTGAAGGATAAGATTA-3’ 
WTUTR(RNA) 5’-Biot-tegugcaauuacaaauauuuccguuuaauuauaacaacaaucuauuGCA-3’ 
isaBRT-
PCRFwd 
5’-GCAAAAGGAAACGAAGCAAG-3’ 
isaBRT-
PCRRev 
5’-AACGACAAACCAGATGCCTAA-3’ 
Trunc-
isaBBam5’ 
5’-GGATCCGCAATAACCCCATATTATAC-3’ 
Trunc-
isaBXho3’ 
5’-CTCGAGTTATTTACTTGTTTTGTATGG-3’ 
isaBNorthern 5’CGTTTTAGCTAATTTAATACCATTGAATTTCACATTATCATAC
TTAATCGCG-3’ 
16sRT-
PCRFwd 
5’-GAACCGCATGGTTCAAAAGT-3’ 
16sRT-PCRRev 5’-TATGCATCGTTGCCTTGGTA-3’ 
IsaBprobe 5’GTATCTGCATCCAAGCACATTACATAATCATATGAAGCCTGT
TTAATGCC-3’ 
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(Qiagen, Valencia, CA) was used with some modification.  Samples were thawed on ice 
and immediately resuspended in 500 µl RLT® lysis buffer (Qiagen), mixed, and added to 
Lysing Matrix B® tubes (MP Biomedicals, Solon, OH).  500 µl Acid Phenol:Choloroform 
(Ambion, Austin, TX) was added to the sample, which was mixed by inverting and 
immediately processed in a FastPrep-FP120 (MP Biomedicals) at a speed setting of 6.0 for 
45s. The tubes were cooled 5min on ice and the bead beating was repeated.  Samples were 
centrifuged at 14,000 rpm for 7 min at 4℃. The aqueous phase was collected and 500µl 
100% ETOH (Invitrogen, Carlsbad, CA) was added and mixed.  Samples were then loaded 
into the RNAeasy column (Qiagen).  Following the manufacturers’ instructions, columns 
were washed with 700µl RW1 (Qiagen) followed by 2X washes of RPE (Qiagen).  The 
RNA was eluted twice with 50µl nuclease-free H20 (American Bioanalytical).  Eluted 
RNA was immediately treated with TurboDNAse (Ambion) according to the 
manufacturer’s instructions, for 30-40 min.  TurboDNAse was inactivated and removed 
using DNAse Inactivation Reagent (Ambion) according to manufacturers instructions.  A 
NanoDrop1000 spectrophotometer (Thermo Scientific, Milford, MA) was used to obtain 
the readings at 230ηm, 260ηm and 280ηm in order to determine the RNA concentration 
and the amount of protein/ethanol contamination.  Absorbancy at 280ηm was used to 
determine the amount of protein contamination with a 260/280 ratio of 2.0 being ideal.  
The 230ηm absorbency was used to determine the relative amount of ethanol 
contamination from the extraction procedure.  RNA concentration was determined from 
the 260ηm absorbency using the following equation: 44ug/ml x OD260nm.   
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Northern Blot Analysis 
Northern analysis was performed using the NorthernMax®−Gly Kit (Ambion, Austin, 
Texas) according to the manufacturer’s instructions.  20µg of RNA was used per sample.  
ULTRAhyb®−Oligo Hybridization Buffer (Ambion) was used instead of the hybridization 
buffer contained in the kit.  The ULTRAhyb®−Oligo Hybridization Buffer protocol was 
followed per the manufacturer’s instructions from pre-hybridization until the final washes.  
The biotinylated nucleotide “IsabNorthern” was used as the probe.  
BrightStar®−BioDetect Kit (Ambion) was used following the manufacturer’s instructions 
for detection and the blots were exposed to autoradiographic film. 
 
Cellular localization of IsaB 
Sa113 and Sa113∆isaB were grown in 1L TSB for 6-10 hours.  Cultures were centrifuged 
and both the cell pellet and spent medium were collected.  Protein from 400 ml spent 
medium was precipitated by 70% saturation (NH4)2SO4, while stirring at 4°C for 1 hour.  
Precipitated proteins were collected by centrifugation, the resulting pellet was resuspended 
in 1 ml of PBS with complete protease inhibitor cocktail tablets (Roche Diagnostics).  The 
samples were dialyzed against 3 L of 0.1X PBS overnight at 4°C before gel 
electrophoresis.  The cell pellet was washed with PBS and resuspended in 20 ml of Buffer 
A (40mM Tris-Cl, 100 mM NaCl, 27% Sucrose, 20 mM MgCl2, and protease inhibitor 
cocktail 1/50 ml).  500 µg lysostaphin was added and the cells were incubated for 4 hours 
at 37°C.  The pellet (protoplasts) and supernatant (peptidoglycan) were separated by 
centrifugation.  The cell pellet was resuspended in 10 ml of water, 1% Triton X was added 
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and mixture was rocked for 10 min at RT.  Samples were centrifuged 10,000Xg for 20 min 
to remove intact cells and membranes were collected by centrifugation at 100,000Xg for 1 
hr.  Following centrifugation the supernatant (cytoplasm) was collected and the pellet 
(membrane) was resuspended in water.  Equal amounts of protein from the four cellular 
fractions were analyzed by denaturing PAGE using NuPAGE® 4-12% Bis-Tris gels 
(Invitrogen) according to manufacturer’s instructions. The proteins were transferred onto a 
PVDF membrane which was then blocked 1 hr in PBS containing 5% skim milk.  The blot 
was probed with a 1:5,000 dilution of IsaB-specific rabbit antisera in PBS containing 
0.05% tween (PBST) and 0.5% skim milk followed by a 1:10,000 fold dilution of goat 
anti-rabbit horseradish peroxidase conjugated IgG in PBST. Proteins were detected using 
the ECL Plus detection system (Amersham) and analyzed with a CCD camera (Kodak). 
 
Quantitative RT-PCR 
1µg of RNA from each sample was converted into cDNA by a two-step reverse 
transcriptase reaction using Superscript II Reverse Transcriptase kit (Invitrogen, Carlsbad, 
Ca) following the manufacturer’s instructions.  The RNA, and 1:10 dilution of (10pM) of 
primers isaBRT-PCRRev and 16sRT-PCRRev were combined and heated @ 70°C for 10 
minutes.  Samples were snap cooled on ice for at least 30 seconds.  Following incubation 
on ice, the reverse transcriptase mixture was added each to sample and incubated at 42°C 
for 2 hours, followed by 15 minutes at 70°C.  The cDNA was diluted 1:10 for isaB samples 
and 1:1000 for the 16s samples.  These samples were subjected to RT-PCR using the 
SensiMix Plus, SYBR® + FLUORESEIN (Bioline, Randolph, Ma) following the 
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manufacturer’s instructions.  Real-Time RT PCR was performed using the following cycle 
conditions: 1 cycle 95°C for 3 min.; 40 cycles of 10 sec 95°C, 30 sec 58°C and 15 sec 
72°C (realtime data collection) followed by a melt-curve using 1:10 dilutions of isaBRT-
PCRRev+isaBRT-PCRFwd or 16sRT-PCRRev+16sRT-PCRFwd.  Cycle thresholds from 
the isaB samples and 16S rRNA samples were used to determine the normalized 
expression (E) of isaB, using the equation E=2^(16s ct – isaB ct).  Samples lacking the 
reverse transcriptase enzyme were assembled as controls for contamination of the RNA 
samples with genomic DNA, and each PCR run included a no template control. 
 
RNA Stability Assay 
Performed essentially as described in Roberts et al, with the following modifications [89].  
Overnight cultures of Sa113 grown in LB were diluted 1:100 in fresh LBG or LBG 
supplemented with 50mM HEPES Buffer (USB Corporation, Cleveland, OH) at a flask to 
volume ratio of 1:2.5 and grown at 37℃ with shaking at 200rpm for 6 hours.  200µg/ml 
rifampin was added to cultures and time-points collected at 0, 5, 30 and 60 min.  Each 
sample was immediately treated with ice-cold RNAlater® (Ambion) and centrifuged at 
4℃ for 10min and pellets were immediately frozen at -80℃ until RNA extraction was 
performed followed with RT-RT-PCR. 
 
Expression of IsaB in E. coli  
BL21-pLysS(DE3)-pRIL + isaB strain of E. coli (Stratagene, La Jolla, CA) previously 
constructed was used. 1L of LB containing 50 µg/ml kanamycin and 35 µg/ml 
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chloramphenicol was inoculated with 50 mL of overnight culture and incubated at 37ºC for 
3 hours.  The culture was induced with 1 mM IPTG and incubated 3 hours at 37ºC. The 
bacteria were collected by centrifugation, and resuspended in 25 ml of CBD buffer (20mM 
Tris-CL pH 7.0 containing 0.5M NaCl) with 0.1% Triton X-100 and protease inhibitors 
(Roche, Indianapolis, IN).  The bacteria were lysed using a French pressure cell followed 
by 6 X 20 sec, 9 Watt pulses with a probe-type sonicator. Intact cells and debris were 
removed by centrifugation, and the supernatant was filtered through a 0.45 µm filter. 8 mL 
chitin resin (New England Biolabs, Ipswitch, MA) was poured into a column, washed once 
with 10 mL H2O and twice with CBD buffer. The lysate was applied to the column, and 
the column was rinsed 3X with 15 ml of CBD buffer, once with 15 mL CBD buffer 
containing 1% TritonX-100, 3X with 15 mL CBD buffer, and finally with 15 mL CBD 
buffer containing 50 mM dithiothreitol (DTT), and the column was incubated 16 hours at 4 
ºC. The column was eluted with 50 mL of CBD buffer and the eluate was concentrated and 
desalted using 5,000 MW Amicon Ultra® concentrators (Millipore Corporation, Billerica, 
MA).  
 
Electrophoretic mobility shift analysis 
Probes for EMSAs were fluorescently labeled with the ULYSIS™ Alexa Fluor® 594 
Nucleic Acid labeling kit (Invitrogen) according to manufacturer’s instructions. Mobility 
shift reaction mixtures containing 20 µL binding buffer (BB1: 20mM HEPES, 1mM DTT, 
20 mM KCl, 200 µg BSA/ml, 10% glycerol), 480 pmol purified, recombinant IsaB 
(optimal concentration determined from Fig. 3A, which had either 3.84 nmol, 1.92 nmol, 
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960 pmol, 480 pmol, or 240 pmol of purified, recombinant IsaB), and 270 pmol RNA 
probe icaUTR6 were incubated for 10 minutes at room temperature. The reactions were 
loaded onto a 2% acrylamide gel, bromophenol blue was added to one lane as a marker, 
and the gel was electrophoresed at 100V for 30 min. Bands were visualized using a CCD 
camera. Salmon sperm DNA (SSS) was serially diluted 10-fold and added to designated 
reactions at final concentrations ranging from 1.35 nmol-1.35 pmol.  For inhibition 
analysis, 2.7 nmol of either salmon sperm DNA (Invitrogen), nucleotides, or yeast tRNA 
(Sigma, St. Louis, MO) were added in addition to the standard mobility shift reaction 
mixtures.  
 
Surface Plasmon Resonance 
IsaB interactions with RNA, DNA, and dsDNA were analyzed using a BIAcore Model 
T100 (GE Healthcare, Piscataway, NJ) following manufacturer’s instructions.  
Biotinylated oligos, DNA and RNA, were immobilized on a Streptavidin chip (SA sensor 
chip, GE Healthcare) in 0.33X HBS-EP buffer, supplemented with 1x of non-specific 
binding inhibitor (GE Healthcare).  Double-stranded DNA was created by loading the SA 
DNA coated chip with the complementary strand, icaRcloneFWD. The first flow chamber 
was left blank to allow for normalization and subtraction of non-specific binding. 
Resonance units were determined using decreasing concentrations of IsaB that were loaded 
onto the chip at a flow rate of 30 µl/min.  The kD and kA were determined with the BIA 
Evaluation Software version 3.0. 
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S. aureus binding to fluorescently labeled oligonucleotide 
Overnight cultures of S. aureus strains 10833 and 10833∆isaB  were diluted 1:20 in fresh 
media (TSB+1% glucose) and incubated at 37°C with shaking.  After 4 hours of 
incubation, approximately 108 bacteria were collected by centrifugation and resuspended in 
binding buffer (20mM HEPES, 1mM DTT, 20 mM KCl, 200 µg BSA/ml).  40ng 
ULYSIS™ Alexa Fluor® 488-labeled sonicated salmon sperm (SSS) was added and the 
reactions were incubated for 15 minutes at room temperature.  Control reactions lacked the 
fluorescent oligonucleotide. Following incubation, the cells were washed once in binding 
buffer, and resuspended in 200 ml of water.  Fluorescent counts were determined using an 
Flx800 (BioTek, Winooski, VT). Experiments were performed in triplicate and statistical 
significance was determined using an unpaired Student’s t-test. 
 
Growth Curves 
Overnight cultures of 10833 or 10833ΔisaB were grown in LB, were diluted 1:100 in fresh 
LB or LBG with a media to flask ratio of 1:2.5.  Cultures were grown at 37℃ with shaking 
at 200 rpm.  At the indicated time-points 1 ml of culture was removed and analyzed with a 
BioMate3 spetrophotometer at (Thermo Scientific) at OD600, to determine culture density, 
and plotted from time 0.   
 
C. elegans Killing Assay 
In these experiments we used a protocol adapted from Begun et al [90]. Briefly, C. elegans 
were allowed to feed on a lawn of S. aureus on LB agar containing 1% glucose and 5mg 
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nalidixic acid/mL.  S. aureus was grown for 4-6hrs at 37ºC on the plate prior to addition of 
C. elegans. 10 nematodes were added per plate (each strain was tested in duplicate) and 
placed at room temperature.  C. elegans that failed to respond to touch were considered 
dead and were counted over a five-day period.  We tested S. aureus strains 10833, its 
isogenic isaB deletion mutant (10833∆isaB), and a strain complemented for the deletion in 
trans by a multi-copy plasmid containing the isaB gene under control of an inducible 
promoter (10833∆isaB+isaB). OP50 is an avirulent strain of E. coli that was used as a 
negative control. 
 
Survival in Whole Blood 
Whole human blood was purchased from Biochemed (Winchester, VA) for use in survival 
assays.  Overnight cultures of S. aureus strains Sa113 and Sa113ΔisaB were grown 
overnight in TSBG and used the following day.  Cultures were diluted 1:50 in whole blood 
and samples were collected at 30 minutes, 2 and 4 hours.  Red blood cells were lysed by 
sonication, samples were collected by centrifugation, resuspended in water and sonicated 
again.  Cells were collected by centrifugation and resuspended in LB prior to plating for 
CFUs.  Percent survival was determined from CFUs of blood treated samples to the CFUs 
of the input culture: (CFU blood/ CFU input)*100. 
 
Invasion Assays 
In order to determine intracellular survival in epithelial cells we used a protocol adapted 
from Hess et al [30].  Briefly, lung epithelial A549 cells were grown to confluence in 
   
 25 
standard tissue culture six well plates with 3mls RPM1 (Gibco, Grand Island, NY).  100ml 
of bacteria at OD600 0.5 were added to the epithelial cells and cocultured for one hour at 
37ºC.  Following incubation, 100 µg/ml of gentamicin was added to the co-culture to kill 
extracellular bacteria. Following gentamicin treatment, the epithelial cells were lysed with 
EDTA+ 0.1% saponin, and the bacteria serially diluted and plated.  Enumeration of CFUs 
was done the following day, and “percent invasive” was calculated by taking the number 
of (CFUs of invasive/CFUs input)*100 per strain.  Thus wild-type and ΔisaB were 
compared by “percent invasive”.  
 
Adherence Assays 
This assay was performed essentially as described for the invasion assay, however cells 
were lysed following the first 1 hour co-culture and CFUs were plated.  Comparisons were 
made using “percent adherent” again using input culture as a means to normalize cultures. 
 
Neutrophil Bactericidal Assay  
Neutrophil mediated killing via phagocytosis was performed using a protocol adapted from 
Corbin et al, to assess the ability of IsaB to protect S. aureus from neutrophil mediated 
killing [91].  Briefly, cultures of S. aureus strains 10833 and 10833ΔisaB were grown 
overnight in TSBG.  The bacterial cells were pre-opsonized with 50% human serum/50% 
PBS at 37℃ for 30 minutes, which allowed for complement and antibody deposition.  
Meanwhile, human neutrophils were isolated using a Ficol sucrcose gradient and red blood 
cells were lysed using a water wash.  2x107 neutrophils were co-cultured with the pre-
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opsonized bacteria at an MOI of 1 for 2 hours at 37℃ with rotation.  Neutrophils were then 
lysed with saponin, samples were sonicated and then plated for CFUs.  Percent survival 
from neutrophil mediated killing was determined using the following equation:  (CFUs 
neutrophil/ CFUs pre-opsonized input)*100.  
 
NETs Killing Assay 
Performed using a protocol adapted from Jann et al [92].  Neutrophils were isolated from 
whole blood separated with a Ficol sucrose gradient.  500,000 cells were added to wells in 
a 96 well plate and treated with 50nM PMA in RPMI for 4 hours at 37℃. Neutrophil 
media was replaced with fresh RPMI containing 10nM cytochalsin D. For bacteria, 
overnight cultures of Sa113 and Sa113ΔisaB grown in LBG.  Bacteria were washed in 
RPMI and 1x103 bacteria were co-cultured with the NETs for 30 minutes.  Samples were 
sonicated briefly with a probe-type dismembranator, and CFUs were used to enumerate 
killing by NETs.  Percent survival was determined by the following equation:  (CFUs 
treated/CFUs input)*100. Statistical analysis was done using the Student’s t-test with 
significance cutoff of p < 0.05. 
 
AMP Survival Assays 
S. aureus strain 10833 and 10833ΔisaB were grown overnight in LBG.  Bacteria from 
100µl of overnight cultures were collected by centrifugation and resuspended in 1 ml of 
PBS.  10µl of the bacteria, containing approximately 1X106 bacteria was added to 100µl of 
PBS.  Experimental samples were treated with 2.4µg/ml of each HNP1 (PeproTech Inc, 
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Rocky Hill, NJ), HBD2 (PeproTech Inc), Buforin (AnaSpec Inc, San Jose, CA), and HBD3 
(PeproTech Inc) and controls were left untreated.  AMPs and bacteria were incubated 
together for 2 hours at 37℃ with rotation.  Samples were sonicated briefly and then plated 
for CFU enumeration of percent survival.  Percent survival was calculated by the following 
equation:  (CFUs treated/CFUs control)*100.  Statistical analysis was done using the 
Student’s t-test with significance cutoff of p < 0.05. 
 
Confocal Microscopy 
Overnight cultures of either 10833, or 10833∆isaB grown in TSB were diluted 1:20 and 
added to wells of a 6-well tissue culture plate.  After overnight growth the media was 
removed and biofilms were resuspended in PBS and stained with Live/Dead® BacLight™ 
Bacterial Viability Kit (Molecular Probes) following manufacturer’s instructions.  Stained 
biofilms were visualized with a   Zeiss confocal scanning laser microscope. 
 
96 Well Biofilm Micro-titer Plate Assay 
Biofilm assays were performed essentially as described by Christensen [93]. Overnight 
cultures of S. aureus strains 10833, 10833∆isaB, Sa113, and Sa113∆isaB were diluted 1:20 
in fresh media (TSB, TSBG, TSBG +3.5% NaCl, BHI, BHIG, LB, or LBG) in a microtiter 
plate.  Cultures were incubated overnight at 37°C.  The following day, the media was 
removed, plates were washed with 1X PBS, dried and stained with safranin.  For 
visualization of biofilms, images were obtained by the use of an image scanner. Stained 
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biofilms were resuspended in 100µl in 33% acetic acid and absorbency at 564nm was 
determined using an ELISA plate reader.  
For DNAse treated biofilms the same protocol was followed with the addition of 
treatment with experimental biofilms with 2.5U TurboDNase per sample.  DNase was 
incubated with the biofilms for 4 hours before processing as normal.  The control biofilms 
were processed prior to the 4 hour incubation.  Percent degradation was calculated by 
comparing the mean biofilm absorbency on the control plate to the mean biofilm 
absorbency of the biofilms treated with TurboDNase; (treated biofilm/control 
biofilm)*100. 
Serum biofilm formation was assessed with the standard amount of cells being 
inoculated directly into 100%, 50%, 25%, 12.5%, or 6.25% human serum.  Serum dilutions 
(when required) were made with TSBG.  
 
Western Analysis  
Performed essentially as described above for “Cellular Location of IsaB”.  Samples were 
collected by centrifugation at 4,000 rpm for 15 min and resuspended in 250µl of 5%SDS, 
and incubated at room temperature with agitation for 30 min.  Following SDS treatment, 
the bacteria were centrifuged at 13,300 rpm for 5 minutes, and the cleared supernatant, 
containing the soluble protein, was collected.  200 µg of protein/sample was used. Then 
treated as described above.  
 For western time course, the cells were diluted 1:100 from overnight LB cultures 
into LB, LBG, or LBG + 50mM HEPES.  10 ml samples were taken at time-points 2, 4, 6, 
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8, and 24 hours.  Cells were collected and processed with SDS as described above.  
Supernatant from these cultures was concentrated 10X using micron-concentrators 
(Millipore) with LDS buffer being added directly to samples and processed normally. 
 For surface-association assays, 5 mls of overnight culture of indicated strains were 
grown in TSBG.  Cells and supernatant were separated by centrifugation.  Cells were 
treated as described above and supernatants were concentrated as described previously. 
 
Expression and Purfication of m-IsaB. 
The mature isaB (m-isaB) gene excluding the signal sequence was amplified from Sa113 
total DNA by PCR using primers truncIsaB-Bam and truncIsaB-Xho.  The PCR product 
was digested with BamI and XhoI (New England BioLabs)and cloned into the pET32-XT 
vector (kindly provided by Dr. David Willaims) using Ready-to-go ligase (Amersham, 
Piscataway, NJ).  The pET32-XT vector fuses an amino terminal thioredoxin-6His onto the 
protein.  The ligation reaction was used to transform TOP10 E. coli (Invitrogen) and 
successful transformants were selected by resistance to 100 µg/ml ampicillin.  The plasmid 
was sequenced to confirm the lack of mutations within m-isaB and was used to transform 
the BL21-(DE3)-pRIL strain of E. coli (Stratagene, La Jolla, CA). 1L of LB containing 
100 µg/ml ampicillin and 35 µg/ml chloramphenicol was inoculated with 50 mL of 
overnight culture and incubated at 37ºC for 3 hours.  The culture was induced with 1 mM 
IPTG and incubated 3 hours at 37ºC. The bacteria were collected by centrifugation, 
washed in PBS and the pellet frozen at -80℃.  Cells were lysed with BPER lysing reagent 
(Invitrogen) supplemented with 150mM NaCl and 2mM β-Merceptoethanol.  Lysates were 
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cleared via centrifugation and immediately loaded into Akta HPLC and separated over a 
nickel column.  Protein peaks were collected and then dialyzed against 3L of 20mM Tris-
HCL pH 8.0 with 2mM β-Me and 150mM NaCl using a 10,000 mw Slide-A-Lyzer® 
Dialysis Cassette from (Thermo Scientific).  150U Thrombin was added to the dialysis 
reaction which was incubated at RT overnight.  Dialyzed samples were again loaded into 
the Akta and m-IsaB was separated over a mono-S ion exchange column.  Protein peaks 
were collected and then purified once more over a large gel filtration column.  Protein 
concentration was determined using the 280ηm on a spectrophotometer using the equation: 
(absorbance at 280nm*dilution factor)/extinction coefficient.  The extiniction coefficient 
used was 1.292 as was determined for m-IsaB using the ExPasy ProtParam Tool, available 
at http://expasy.org/cgi-bin/protparam[94].  To ensure purity ~5 µg of protein was used and 
NuPAGE® LDS Sample Buffer (4X)  was added to samples and then heated at 75°C for 
10 minutes.  Following the denaturation step, the samples were loaded onto NuPAGE® 4-
12% Bis-Tris Gel 1.5mm x 10 well and electrophoresed for 30 minutes at 200V.  After gel 
electrolysis, the gel was washed once in 50mls of dH2O followed by staining with 
Imperial™ Protein Stain (Thermo) according to the manufacturer’s instructions.  The 
stained gel was then decolorized with 3X 50mls washes with dH2O until no background 
staining was observed.   
 Labeling procedure was adapted from Cai et al [95].  Briefly, 13C-glucose and 
15NH4Cl (Cambridge Isotope Laboratories Inc., Andover, MA) were provided as the sole 
carbon and nitrogen source to ensure isotope incorporation into the protein.  For expression 
of labeled m-IsaB, BL21+m-isaB was grown overnight in 1LB at 37℃, 500 µl were used 
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to inoculate 10mls of M9 buffer (containing both 13C-glucose and 15NH4Cl) which was 
grown for approximately 8 hours at 37℃.  10ml was then used to inoculate 100mls of M9 
buffer that was then grown overnight at 37℃.  The overnight culture was inoculated into 
1L of M9 and grown to an OD600 of 0.8, where it was then induced with the addition of 
1mM IPTG and incubated for 4 hours before cells were collected by centrifugation and 
storage at -80℃.  Samples were then subjected to the purification process previously 
described for m-IsaB. 
 
m-IsaB EMSA 
Mobility shift reaction mixtures containing 20 mL binding buffer (BB1: 20mM HEPES, 
1mM DTT, 20 mM KCl, 200 µg BSA/ml, 10% glycerol), with either 1.6 nmol, 160pmol, 
16pmol, or 0.16pmol  purified, recombinant m-IsaB, and 1 fmol biotinylated probe 
IsaBprobe were incubated for 20 minutes at room temperature. The reactions were loaded 
onto a 2% acrylamide gel, bromophenol blue was added to one lane as a marker, and the 
gel was electrophoresed at 100V for 30 min.  The gel was then transferred to a 
BrightStar®-Plus Positively charged nylon membrane (Ambion) by wet-transfer at 30V for 
1 hour.  The membrane was then blocked, probed, washed, and developed using the 
Chemiluminescent Nucleic Acid Detection Module (Thermo Scientific) according to the 
manufacturer instructions.  
 For teichoic acid competition assay lipoteichoic acid (LTA) (Sigma Aldrich, St. 
Louis, MO) was used.  The above EMSA reaction containing 160nmol of purified 
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recombinant IsaB (optimal shift) was used with the addition of LTA at a concentration of 
1µg, 100ηg or 10ηg.  Reactions were then completed as described above. 
 
Assay for Degradation of DNA by m-IsaB 
EMSA reactions setup as described above using either 1.6pmol or 160nmol IsaB in either 
BB1 or in BB1 where 20mM HEPES buffer was replaced with 20mM phosphate buffer pH 
5.8.  Samples were incubated at RT for 30min and then treated with 2X Novex®® TBE-
Urea Sample Buffer (Invitrogen) and heated for 3min at 75℃.  Samples were then loaded 
onto a 15% TBE-Urea gel (Invitrogen) and electrophoresed at 100V for 2 hours.  Samples 
were then transferred and reacted as described previously using the Chemiluminescent 
Nucleic Acid Detection Module. 
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CHAPTER 3 
 Regulation of IsaB 
 
  
  
Introduction: 
The observation by Lorenz et al. that IsaB elicits an antibody response during acute 
infection but not during colonization led us to hypothesize that expression of IsaB is 
induced during active infection, and that this expression has a role in the modulation of S. 
aureus virulence [87].  The expression of IsaB during sepsis may contribute to disease 
progression and the characteristic robust immune response seen in these patients, whereas 
suppression of IsaB during colonization may contribute to the lack of a specific immune 
response to this protein in carriers.  Further suggestive of its relationship to infection, other 
labs have reported microarray data showing isaB expression to be increased; 1.) in 
response to neutrophil exposure, 2.) in biofilms, 3.) under anaerobic conditions and 4.) 
following internalization in human epithelial cells [2, 49, 96, 97].  All of these phenomena 
support the hypothesis that IsaB is a virulence factor of S. aureus.   
Because the function of IsaB in vivo was unknown, we first wanted to determine 
the regulation of isaB.  A number of global regulators in S. aureus, such as SarA, control 
the expression of genes within a specific regulon.  Characterization of the regulatory 
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network, and inducing stimuli, of isaB would serve as a foundation for a hypothesis 
regarding the role of IsaB in the virulence of S. aureus.   Therefore we began our studies 
by determining the stimuli responsible for inducing isaB expression and how global 
regulators affected expression.  
 
Results: 
isaB is Transcribed as a Single Transcript 
To begin our studies we first examined the location of isaB on the chromosome to 
determine the likelihood of it existing within an operon, which could lead to clues to its 
function or regulation.  Figure 1 shows the surrounding genes of isaB, and as the 
schematic shows, isaB does not appear to be located within an operon.  However, we were 
intrigued by the possibility that isaB and aur, the gene encoding for aureolysin, were 
cotranscribed, as aur is immediately downstream of isaB.  Aureolysin is a previously 
described extracellular zinc-metalloprotease that contributes to the virulence of S. aureus.  
To address whether isaB and aur were cotranscribed, Northern blot analysis was used to 
determine the size of message recognized by the biotinylated isaB specific probe.  As 
shown in Figure 2 we detected a message of approximately 500 bases, which is consistent 
with predicted size of the isaB transcript alone.  If the two genes were co-transcribed, then 
a transcript of approximately 2,000 bases would have been observed. Therefore, isaB is not 
located within an operon and is it not co-transcribed with the immediately downstream aur 
gene.  
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Figure 1.  Chromosomal Location of isaB.  isaB and immediately 
surrounding genes on the chromosome of S. aureus strain Col.  Arrows 
indicate the direction of transcription. 
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Figure 1.  Chromosomal Location of isaB. 
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Figure 2.  isaB is a Monocystronic Transcript.  If isaB was co- 
transcribed with aur a band with the predicted size of ~2000 bp would be 
observed by Northern blot analysis. Using a biotinylated isaB specific 
probe, a band corresponding to the predicted 566 bp size of the isaB 
transcript was observed. 
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 Figure 2.  isaB is a Monocystronic Transcript. 
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 IsaB is Secreted 
 In Gram-positive bacteria most virulence factors are exposed on the cell surface or 
secreted into the extracellular milieu in order to function against the adverse conditions 
found in vivo [7].  S. aureus generally uses its sec-pathway for translocation of proteins 
across the cell membrane, which are targeted for export by a N-terminal signal peptide 
sequences.  Following translocation of the protein, the signal peptide sequence is cleaved 
by the signal peptidase SpsB releasing the mature protein [7, 98].  Using the prediction 
server PSORTb we found that, like other virulence factors, IsaB was predicted to have an 
N-terminal signal peptide sequence for secretion [99].  Therefore Western blot analysis 
was used to confirm the predicted extracellular location of IsaB.  Stationary phase cultures 
of S. aureus were fractionated into cell surface associated, supernatant, membrane 
associated and cytoplasmic fractions.  The presence of IsaB in these fractions was detected 
using anti-IsaB Rabbit anti-serum.  As shown in Figure 3, IsaB was detected exclusively 
on the cell surface and in the spent medium.  Therefore IsaB is secreted from S. aureus, 
likely through the sec-pathway due to the presence of an N-terminal signal peptide 
sequence. 
 
isaB is Not Regulated Temporally Under Normal Culture Conditions    
While IsaB has been shown to be immunogenic, which lead to our hypothesis that 
it is expressed in vivo, no information was known about its expression under normal 
laboratory conditions.  S. aureus encodes numerous “accessory” genes that are directly 
related to pathogenesis, which are often described as the “virulon” [100]. 
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Figure 3.  IsaB is Secreted. Sa113 and Sa113∆isaB cultures were 
fractionated into: supernatant (lanes 1 and 2), cell wall associated (lanes 3 
and 4), cell membrane (lanes 5 and 6) and cytoplasmic (lanes 7 and 8) 
fractions.  IsaB bands were observed in both the supernatant and cell wall 
associated fractions in wild-type Sa113 (lanes 1 and 3, arrows) but not in 
Sa113∆isaB (lanes 2 and 4 respectively). Proteins that reacted non-
specifically with IsaB antiserum were observed in all lanes, but were 
present in the isaB mutant as well as wild-type.  
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 Figure 3.  IsaB is Secreted. 
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The expression of many of these virulence factors and other genes in S. aureus can be 
dependent upon external signals; however many are regulated temporally dependent upon 
growth stage and culture density.  This temporal regulation is carried about by numerous 
transcription factors and/or two-component systems such as the transcriptional regulator 
SarA, or the Agr two-component system [100-102]. Therefore we sought to determine if 
isaB is temporally regulated during in vitro culture conditions, including growth in 
complex rich media such as Luria Bertani Broth (LB).  Overnight cultures of wild-type S. 
aureus strain(s) were diluted 1:100 in fresh LB and samples collected at time-points 2, 4, 
6, 8, 24, 48, and 72 hours.  RNA was extracted from the samples and analyzed by 
quantitative reverse transcriptase PCR, RT-PCR.  Following normalization with the 
internal control, 16s rRNA, it was found that isaB is expressed at a fairly consistent level 
throughout the time course varying only slightly (< 2 fold), until 72 hours post-dilution, 
where we observed an approximately 4.5 fold reduction in isaB expression, as shown in 
Figure 4.  This data suggests that isaB under normal conditions is not significantly 
temporally regulated. 
 
Glucose and Other Simple Sugars Induce isaB Expression. 
IsaB stimulates an antibody response during septicemia.  Therefore potential “in 
vivo” cues were assessed for their ability to induce isaB expression.  The first cue tested 
was glucose, which would be available to the organism in blood during septicemia.  
Previously, glucose has been shown to both activate and repress transcription of factors 
associated with virulence; this discrepancy is likely due to environmental and metabolic  
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Figure 4.  isaB Does Not Exhibit Significant Temporal Regulation.  
To determine if isaB is temporally regulated throughout the growth cycle 
of S. aureus, RT-PCR of S. aureus strain Sa113 grown in LB was 
performed.  Time-points were taken post-dilution into fresh media and 
normalized to the 16s rRNA ct.  No significant amount of temporal 
regulation was observed. 
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Figure 4.  isaB Does Not Exhibit Significant Temporal 
Regulation. 
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cues that regulate disease progression by S. aureus [84, 85, 87].  Therefore, overnight 
cultures of wild-type S. aureus were diluted 1:100 in fresh media, containing 1% glucose, 
LBG, which is approximately 10X greater than concentrations likely experienced in vivo 
[103].  Following six hours of induction samples were collected and RNA extracted for 
analysis by Northern Blots.  
As shown in Figure 5a, after six hours of growth in glucose a dramatic increase in 
the amount of isaB message was detected by Northern blot.  In order to quantify the 
magnitude of the change in expression due to glucose, RT-PCR was employed.  As shown 
in Figure 5b, upon induction with 1% glucose isaB transcript increases approximately 14-
fold relative to media without glucose.  Carbon uptake and metabolism in S. aureus is 
controlled by a complex regulatory network, known as the phosphotransferase system 
(PTS), and is largely dependent on the type of carbon source available, i.e. preferred versus 
non-preferred [81, 84, 104, 105].  Fructose and sucrose, both simples sugars that can be 
used in glycolysis were next tested for their ability to induce isaB, again utilizing RT-PCR 
[79].  As shown in Figure 5b, both fructose and sucrose were capable of increasing 
detectable isaB transcript by approximately 13 and 8 fold, respectively.   
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Figure 5.  isaB Expression is Induced by Sugar(s).  To determine if 
isaB is induced by glucose or other sugars S. aureus strains were grown 
in LB, LBG, LB+Sucrose (LBS) and LB+Fructose (LBF) for 4 hours 
before isaB transcript analysis. a) Northern blot analysis of isaB levels in 
S. aureus strain 10833 grown in either LB or LBG shows a dramatic 
increase in the level of transcript detected.  b) RT-PCR of 10833 grown 
in LB, LBG, LBF, or LBS.  The greatest increase of isaB was observed in 
samples grown in LBG followed by LBF, and LBS with fold increases of 
13.5, 12.5, and 7.8 respectively.  All samples were normalized to 16s 
rRNA ct values.  
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Figure 5.  isaB expression is Induced by Sugar(s). 
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Maximum isaB Expression Occurs Between 8-24 hours. 
Finally, a long-term time course of glucose induction was performed to determine 
when the maximal induction of isaB occurred, and how long the induction lasts.  Overnight 
cultures were diluted as described above, and samples for RNA extraction were collected 
at 2, 4, 6, 8, 24 post-dilution into LBG.  As shown in Figure 6, isaB expression increases 
over time, with maximal expression observed at approximately 24 hours post dilution into 
media supplemented with 1% glucose.  Similar experiments were performed on two other 
S. aureus strains: Sa113 and 10833, and the same trend was observed with isaB expression 
peaking between 8-24 hours, followed by decreasing levels out to 72 hours. 
 
 m-IsaB Expression Coordinates with isaB Expression. 
To ensure that IsaB was being translated at greater rates in concert with gene 
transcription, western blots were performed to determine relative expression of IsaB.  For 
these experiments, overnight cultures of wild-type and ΔisaB strains were diluted 1:100 in 
LBG, and 5 mls of culture were collected at time-points 2, 4, 6, 8, and 24 hours.  Both cell 
surface associated protein, and concentrated supernatant was taken at each time-point to 
assay any variation in the cell associated and secreted proportions.  ΔisaB samples taken at 
6 and 24 hours were used as a negative control because of the presence of a consistently 
observed cross-reactive band that runs just slightly smaller than IsaB. 
The blots in Figure 7 show that very little IsaB is observed for cell-surface 
associated samples at 2 hours post-dilution.  However by 4 hours IsaB expression was
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Figure 6.  Time-course of isaB Expression in Glucose.  RT-PCR 
analysis 
of isaB expression in S. aureus strain RN496 following growth in 
glucose.  Dark bars indicate cultures grown in LB while light bars 
represent samples grown in LBG.  Time points indicate time after 
dilution into fresh media.  Maximal expression of isaB is observed at 8 
hours post-dilution. All samples were normalized to their 16s rRNA ct 
values. 
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Figure 6.  Time-course of isaB Expression in Glucose. 
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Figure 7.  IsaB Expression is Coordinately Regulated With the 
Gene.  To ensure m-IsaB was being regulated in the same fashion as its 
gene western blot analysis was used.  Cultures of S. aureus strains 10833 
and 10833ΔisaB were diluted 1:100 in LBG.  Samples of both cells and 
supernatants were collected at the time points indicated.  IsaB was 
detected using our anti-IsaB polyclonal antibody.  Very little of IsaB was 
detected at 2 hours post-dilution (left arrow), however like transcript 
maximal expression was observed between 8 and 24 hours (right arrow).  
The non-specific band under the IsaB band is never observed in the 
culture supernatants.  
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Figure 7.  Time-course of IsaB Expression in Glucose. 
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 noticeably increased and continued to increase over the next 20 hours.  Interestingly, IsaB 
was most highly detected in the supernatant fractions between 4-6 hours, with very little 
being observed in the 8 and 24 hour fractions.  These results show that expression of IsaB 
protein undergoes a pattern that is similar to expression of the isaB gene in response to the 
addition of glucose. 
 
Exposure to Serum and/or Plasma Upregulates isaB levels.  
After discovering that simple sugars induce isaB expression, two complex in vivo 
cues, plasma and serum, were tested for their ability to induce isaB transcript levels, again 
using RT-PCR.  Overnight cultures of S. aureus were grown in LB and subsequently 
diluted into either whole human serum or human plasma and grown for 2 hours, before 
collecting samples for RNA extraction using a modified protocol incorporating trizol.  The 
results obtained from these experiments are found in Figure 8, which shows that after two 
hours of incubation in plasma or serum (compared to growth in LB) isaB levels were 
increased by approximately five-fold in each condition, further supporting evidence that 
IsaB is expressed in vivo.  
 
SarA Represses Expression of isaB 
  The staphylococcal accessory regulator A, SarA, is a well characterized 
transcription factor considered to be a global regulator of many virulence genes, and was 
recently suggested, from microarray data by Dunman et al; to repress isaB [106][15]. 
Furthermore, when examining the predicted promoter region of isaB, we found a putative  
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Figure 8.  Plasma and Serum Induce isaB Expression.  To determine 
how isaB was expressed in blood components, RT-PCR of isaB 
expression following incubation in either LB (blue), plasma (purple) or 
serum (yellow) were performed.  Graph shows that incubation in either 
serum or plasma increases isaB expression approximately 5 fold.  All 
values were normalized to their 16s rRNA ct values. 
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Figure 8. Plasma and Serum Induce isaB Expression. 
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SarA binding site, as shown in Figure 9, consisting of TTTTTAT [75, 77].  Utilizing sarA 
isogenic deletion mutants available, the effect of sarA on isaB expression levels was 
determined.  First, overnight cultures of the wild-type Sa113 and Sa113ΔsarA strains were 
diluted as described above, and samples were collected 4 hours post-dilution.  RNA was 
extracted from the collected samples, and using an isaB specific probe, transcript levels 
were observed by Northern blot analysis.  As shown in Figure 10a, upon deletion of sarA 
a marked increase in isaB transcript is observed, suggesting that sarA is a negative 
regulator of isaB.  
 In order to further quantify the level of SarA-mediated repression a long-term 
time-course was performed with the wild-type and ΔsarA strains as previously described in 
LB, with samples collected at 2, 4, 6, 8, and 24 hours.  The results in Figure 10b show that 
at all time-points tested ΔsarA had more isaB transcript present, with fold differences 
ranging from approximately 2 fold to 88 fold over the time-course, with the greatest 
increase of isaB over wild-type observed at 24 hours (88 fold).  These data support the 
conclusion that SarA is a negative regulator of isaB expression.  SarA is a known negative 
regulator of extracellular proteases, enzymes, and other secreted proteins; therefore, 
regulation of isaB expression by SarA is not unexpected [73-75, 106]. 
 
Acidification of Media Following Glycolysis Induces isaB. 
Since isaB was dramatically increased following induction in glucose, we 
hypothesized that the Carbon catabolite protein A, CcpA, of S. aureus could play a role in 
expression of isaB.  We constructed a ccpA isogenic deletion mutant, which would allow  
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Figure 9.  Structure of Predicted IsaB Promoter.  The predicted 
organization of the isaB promoter region, that also contains a putative 
SarA consensus binding sequence.  Bprom promoter finding tool was 
used to predict promoter structure. 
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AAATATAATCATTAGTATTTTTATGGCTGAAAAAGTTATAATAAAAGT
GTAAGGAATAAAATATTTGTATGGAAAAGAGAGATAATTATG… 
-35 -10 
+1 
Translational Start 
Putative SarA Binding Site 
Figure 9.  Structure of Predicted IsaB Promoter. 
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Figure 10.  SarA Negatively Regulates isaB Expression.  To determine 
the ability of SarA to regulate isaB transcription, ΔsarA mutants were 
assessed for differences in isaB levels compared to Wild-type.  a) 
Northern blot analysis of the levels of isaB transcript in S. aureus 10833 
and 10833ΔsarA.  Increased expression is observed in 10833ΔsarA.  b)  
RT-PCR of isaB expression in S. aureus Sa113 (dark) and Sa113ΔsarA 
(light).  Time-points indicate time post dilution into fresh LB.  Deletion 
of SarA leads increased isaB detected at all time-points with the greatest 
difference of 88 fold observed at 24 hours post-dilution into fresh LB. All 
samples were normalized to the 16s rRNA ct values.  
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Figure 10.  SarA Negatively Regulates isaB. 
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for studies to determine the affect ccpA has on isaB expression.  To that end, RT-PCR was 
used to analyze isaB transcript levels between wild-type and ΔccpA strains, using the  
protocol described above with time-points taken at 2, 4, 6, 8, and 24 hours post-dilution.  
As Figure 11 shows, deletion of ccpA led to a dramatic decrease in the amount of isaB 
transcript induced by the presence of glucose.  These findings suggested that isaB 
expression is activated through the carbon catabolite control system, mediated by CcpA. 
We also investigated the possibility that the effect of the glucose was mediated 
through an effect on pH rather than through a direct effect of CcpA.  Through personal 
observation and previously published literature, it is well known that following addition of 
glucose to a growing culture of S. aureus there is a subsequent decrease in the pH of the 
media [87, 107].  To address if pH and not glucose was inducing isaB expression, a time-
course was performed, however in addition to the normal LBG culture, 50mM HEPES was 
added to LBG to effectively buffer the media to prevent or delay the acidification of the 
media without affecting growth [84].  Surprisingly, as shown in Figure 12, when the pH of 
the media was buffered to maintain a neutral pH longer (than unbuffered with glucose) we 
did not observe the typical levels of isaB induction by glucose.  Therefore, it is likely that 
the falling pH, a consequence of carbon metabolism, is in fact turning on isaB expression.  
However it is yet unknown through which pathway the change in pH is acting to cause 
induction of isaB. 
Upon further analysis of isaB levels and fold increases during the pH buffering and 
ΔccpA experiments, it became obvious that the fold decrease from these two experimental  
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Figure 11.  CcpA Activates isaB Expression.  RT-PCR analysis of S. 
aureus Sa113 (dark) and Sa113ΔccpA (light) grown in LBG were used 
to test the CcpA deletion mutants ability to express isaB following 
glucose induction.  Time-points indicate time post-dilution into fresh 
media.  Decreased isaB levels were detected in the CcpA deletion mutant 
from 4 hours post-dilution onward.  All samples were normalized to their 
16s rRNA.  
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Figure 11.  CcpA Activates isaB Expression. 
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Figure 12.  Acidic pH Following Glycolysis Induces isaB.  To 
determine the affect that the decreasing pH following glucose metabolism 
has on expression of isaB in S. aureus, LBG was buffered with 50mM 
HEPES and transcript levels were analyzed using RT-PCR.  Wild-type 
Sa113 was grown in LB, LBG, LBG Buffered or LB Buffered.  Results 
demonstrate show a significant reduction in isaB expression in the 
presence of glucose when media is buffered.  All samples were 
normalized to their 16s rRNA ct values. 
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Figure 12.  Acidic pH Following Glycolysis Induces isaB. 
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conditions were suspiciously similar.  This coupled with the fact that glucose is depleted 
long before maximal isaB induction occurs suggested that pH could be responsible for the 
observed CcpA effect [84, 87]. Therefore culture pH was monitored during a subsequent 
biological repeat of the ΔccpA time-course, and as suspected it was found that the ΔccpA 
mutant grown in LBG exhibited delayed media acidification compared to the wild-type 
strain. This effect is illustrated in Figure 13.  The delayed drop in pH is likely responsible 
for the observed effect that deletion of ccpA had on isaB levels, and therefore from these 
studies it appears that CcpA does not have a direct regulatory role on isaB. 
 
Transcriptional activity rather than mRNA Stability Accounts for the Increase in 
isaB Message. 
 To help further elucidate the apparent regulation of isaB expression by a pH 
dependent mechanism, RNA stability experiments were performed to determine if de novo 
transcription or increased stability was responsible for the rise in detectable isaB transcript 
levels.  For this experiment, overnight cultures of wild-type S. aureus were grown, diluted 
1:100 in either LBG or LBG+50mM HEPES.  Cultures were grown for 6 hours post-
dilution before 200µg/ml rifampin was added and samples taken at 0, 5, 30, and 60 minutes 
to assess the rate of message degradation between “induced” and “buffered” conditions.  
The results of these experiments shown in Figure 14 demonstrate that there does not 
appear to be a significant difference in the rate of degradation, indicating that isaB 
transcript levels are increasing by de novo transcription. 
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Figure 13.  Deletion of CcpA Delays Media Acidification.  pH values 
of S. aureus grown in LB: Sa113 (black dashed line with filled box), 
Sa113ΔccpA (light dashed line with open triangle) or LBG: Sa113 
(black line with open box), Sa113ΔccpA (light line with an x) were 
collected.  Time-points indicate time post-dilution into fresh LBG.  Data 
shows that deletion of CcpA delays the pH decrease following glycolysis. 
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Figure 13.  Deletion of CcpA Delays Media Acidification. 
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Figure 14.  isaB Transcript Stability is Not Affected by pH.  
Transcript levels in the absence of de novo transcription (rifampicin 
treatment) were measured to determine if the increase in isaB is due to 
increased stability or de novo transcription.  RNA stability assay using S. 
aureus Sa113 grown for 6 hours in either LBG (dark circles) or 
LBG+50mM HEPES (light triangles) prior to rifampin treatment.  Time-
points indicate time after addition of 200µg/ml rifampin.  Due to the 
similar slopes of transcript decay observed it does not appear that the 
stability of the isaB transcript is altered. 
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Figure 14.  isaB Transcript Stability is Not Affected by pH. 
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Discussion: 
IsaB was first identified due to its strong immunogenicity during MRSA 
septicemia.  In support of our hypothesis that IsaB is a virulence factor produced during 
infection we found that IsaB is secreted by S. aureus.  This finding suggests that IsaB is 
immunogenic due to its active secretion by S. aureus and not a side-effect of bacterial  
cell lysis, further arguing that IsaB is an important virulence factor.  The above results 
illustrate that regulation of isaB is likely due to a complex regulatory network, with 
expression being orchestrated by external/environmental signals, as well as internal factors, 
such as the SarA transcription factor.  These studies show that the main (as characterized 
thus far) environmental factor that leads to de novo transcription of isaB is not likely 
mediated through glucose or carbon catabolite regulation, but in fact through a drop in pH.  
Importantly, isaB expression does not reach peak levels until long after all glucose in the 
culture is depleted, and the pH has dropped to approximately 5.  Furthermore we found 
that IsaB is translated at rates that coordinate with the observed increase in transcription 
following exposure to glucose and media acidification.   
It important to note that under normal/non-inducing growth conditions isaB does 
not exhibit significant amounts of temporal regulation.  While there was an increase in 
isaB levels at 48 hours it is unknown which stimuli are inducing expression and how 
expression of isaB is important at this late stage of growth.  However an interesting 
observation is that while acidification is delayed, the pH in both the ΔccpA and buffered 
cultures did eventually reach normal/control levels when supplemented with glucose, and 
yet isaB was not highly induced.  Therefore, even though the pH ultimately decreased, 
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isaB expression never reached (in our time-course) levels observed normally. This could 
indicate that isaB is being regulated in a temporal or growth stage specific manner under 
acidic conditions, which could be a consequence of its regulation by SarA, which regulates 
genes temporally, and has recently been shown to be affected by pH [106]. Also it is 
prudent to point out that while most of the upregulation of isaB is ablated by buffering 
conditions, the addition of glucose does appear to have some role in increasing expression 
as the levels observed in the buffered LBG are consistently greater than S. aureus grown in 
buffered LB only. 
Of clinical relevance, these studies have also found that isaB expression increases 
significantly following culture in either serum or plasma.  Again showing that IsaB is 
likely expressed in vivo during septicemia, a systemic infection of the blood, and is likely 
important for S. aureus survival.  However as these fluids are composed of a great number 
of factors, it is unknown which components in are responsible for stimulating increased 
isaB transcription. These results further increase the complexity of the regulation of isaB 
as the same signals or proteins that sense acidic conditions are not likely to be stimulated 
in serum/plasma as these biological fluids are inherently buffered to maintain a tight 
homeostasis at neutral pH.  However, isaB is induced following phagocytosis, where S. 
aureus would be exposed to low pH inside the phagolysosome of neutrophils. Important 
future experiments would be to elucidate through which mechanisms, such as one of the 16 
two-component systems in S. aureus is responsible for each stimulus [69]. 
Finally these studies have demonstrated that SarA is a negative regulator of isaB, 
although it is currently unknown if this is due to direct or indirect regulation.  Two 
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independent labs have proposed consensus sequences for SarA binding sites, one of which 
is 26bps, the other only 7 (with one allowed mismatch) [75, 77].  As Figure 9 highlights, 
the predicted promoter of isaB contains a 6 base pair match to the predicted 7 base pair 
SarA binding consensus sequence, suggesting that isaB could be directly regulated by 
SarA.  However, even the authors caution that S. aureus is very AT rich and the proposed 
consensus sequence of ATTTTAT without direct observation of SarA binding, through 
EMSAs, may not be stringent enough to determine direct binding or regulation by SarA, 
this caveat is especially true as the isaB gene itself contains two of these “consensus” sites 
[77].  
While the studies presented above, give us a great deal of information about the 
regulation of isaB, there may be other regulators as well as other stimuli that regulate 
expression of isaB. Importantly, the increased expression due to serum/plasma gives 
weight and credibility to the hypothesis that IsaB is expressed during septicemia and is 
therefore likely to play a role in pathogenesis of S. aureus. 
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CHAPTER 4 
Nucleic Acid Binding by IsaB 
 
  
Introduction: 
IsaB was previously isolated in our laboratory in an affinity chromatography screen 
for S. aureus proteins that bound to 5-untranslated region (5’-UTR) of the intercellular 
adhesin (ica) transcript.  The primary research focus of the laboratory is on the regulation 
and production of biofilms in S. aureus and other Gram-positive pathogens.  The 
prototypic S. aureus biofilm matrix is primarily composed of the extracellular 
polysaccharide, PNAG, which is encoded by the intracellular adhesin locus, ica.  The 
purpose of the affinity chromatography was to determine if there was an RNA binding 
protein involved in the post-transcriptional regulation of the icaADBC transcript.  The 5’ 
UTR of the icaADBC transcript was used as “bait” to pull down proteins from whole cell 
lysates of S. aureus.  Only one protein was isolated from this screen, the corresponding 
protein band was excised from an SDS-Page gel and used for Mass-spectral analysis to 
determine the peptide composition.  This singular protein was determined to be IsaB 
(Unpublished Data).   
The lab moved forward to validate the regulatory roles for IsaB on icaADBC 
translation and production of PNAG.  Following production of isaB isogenic deletion 
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mutants, changes in icaADBC transcript levels were assessed using RT-PCR and changes 
in the production of PNAG were assessed by immunoblot.  Through these experiments, we 
determined that IsaB had no observable role in post-transcriptional regulation of icaADBC 
nor did it affect PNAG production.  The argument for the lack of a role in PNAG 
production was further strengthened by the fact that our experiments demonstrated IsaB 
secretion and cell wall association [99].  Therefore, IsaB does not have a regulatory role in 
PNAG production, however these studies suggested that IsaB was a novel extracellular 
RNA binding protein.  In this study we sought to further characterize the nucleic acid-
binding activity of IsaB.  
 
Results: 
Purification of IsaB  
IsaB was previously cloned into and expressed in E. coli, using the pKYB1 vector, 
which contains an IPTG-inducible promoter.  Recombinant protein, which included a C-
terminal chitin-binding domain, was purified over a chitin column, and IsaB was released 
from the column by activation of the self-cleaving intein tag by reducing conditions. A 
schematic showing the procedure and a representative SDS-PAGE protein gel are shown in 
Figure 15. 
 
IsaB binds to RNA. 
 The first experiment performed was designed to validate the RNA-binding ability 
of IsaB.  Using the same RNA probe initially used to purify endogenous IsaB, Electro-  
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Figure 15.  Schematic of IsaB Purification.  a) Diagram of purification 
scheme using a chitin-binding domain with an intein tag.  b) Typical 
SDS-Page gel following purification of IsaB at the predicted size of 
approximately 17 kDa. 
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Figure 15.  Schematic of IsaB Purification. 
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Mobility Shift Assays (EMSAs) were performed in order to directly observe IsaB-RNA 
interactions.  EMSA reactions were performed as previously described.  Briefly, the 
fluorescently labeled probe was mixed with varying concentrations of IsaB and allowed to 
incubate at RT for 15 minutes in freshly prepared binding buffer.  These reactions were 
separated electrophoretically over a 5% acraylamide gel, and the probe signal was detected 
by excitation with UV light.  As shown in Figure 16, IsaB was able to bind to the probe 
and retard its movement through the gel (when compared to the probe only control), 
demonstrating that IsaB is readily able to bind to RNA and is a novel extracellular binding 
protein of S. aureus.   
 
IsaB binds to Nucleic Acids. 
To proceed with EMSA analysis, the concentration of IsaB that produced the most 
significant shift was used for all further studies.  However, as shown in Figure 16 there is 
a large amount of RNA/IsaB that was unable to migrate into the gel, likely due to large 
complex formation. The addition of non-specific carrier DNA is generally added to EMSA 
reactions to inhibit non-specific binding and typically breaks up such large complexes 
ensuring that all probe is able to be visualized within the gel.  Therefore, sonicated salmon 
sperm DNA, SSS, was added to the EMSA reactions starting at a 2:1 ratio of SSS to 
labeled probe.  Surprisingly, as Figure 17 shows, the SSS was able to out-compete the 
labeled probe as seen by the ablation of the RNA shift at SSS ratios 2:1 and 0.5:1.  This 
EMSA demonstrates that not only can IsaB interact with RNA, it can also interact with  
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Figure 16.  IsaB Binds RNA.  EMSA reaction showing ability of IsaB to 
shift a fluorescently labeled RNA oligo.  All lanes contained 270 pmol 
labeled RNA: Lane 1, no IsaB control, Lane 2, 3.84 nmol IsaB, Lane 3, 
1.92 nmol IsaB, Lane 4, 960 pmol IsaB, Lane 5, 480 pmol IsaB, Lane 6, 
IsaB.  
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Figure 16.  IsaB Binds RNA. 
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Figure 17.  IsaB Binds Nucleic Acids.  In order to block non-specific 
binding, SSS DNA was added to EMSA reactions.  EMSA reactions 
contained 480 pmol purified IsaB and 270 pmol labeled RNA. Lane 1, 
RNA only, Lane 2 EMSA, Lane 3, EMSA + 1.35 nmolSSS, Lane 4, 
EMSA + 135 pmol SSS, Lane 5, EMSA + 13.5pmol SSS, Lane 6, EMSA 
+ 1.35 pmol SSS.  At the two highest concentrations of DNA the shift 
was ablated indicating that IsaB binds DNA as well. 
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Figure 17.  IsaB Binds Nucleic Acids. 
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DNA, which IsaB appeared to have a slight preference for.  Secondly, this experiment 
strongly suggests that the binding activity observed is non-sequence specific, as SSS, 
which is made up of oligonucleotides of random sequence and size, is able to effectively 
compete with the RNA probe for binding to the protein.  Therefore IsaB is binding to 
nucleic acids, both ds-DNA and ss-RNA, in a non-sequence specific manner. 
 
IsaB Binds Nucleic Acids, Not Nucleotides. 
 Due to the ability of IsaB to bind all nucleic acids tested, its lack of a 
conserved/predicted binding domain, and apparent lack of sequence specificity, we 
considered the possibility that IsaB could have a nucleotide-binding domain.  To 
investigate its nucleotide binding activity, a competitive EMSA was performed.  This 
experiment was performed as described above, however, to each reaction, a 10-fold greater 
concentration of unlabeled competitor to probe was added, either SSS, yeast tRNA, or 
dNTPs.  If IsaB bound to any of these substrates, even if the affinity was less than its 
affinity for the labeled probe, a decrease in the shift should be observed.  Figure 18 
indicates, as expected, that when competitor SSS or tRNA was added to EMSA reactions 
there was no shift observed as IsaB bound to the unlabeled probe added in excess.  
Importantly, in the EMSA reaction supplemented with 10X dNTPs, the labeled RNA probe 
is still shifted, indicating that IsaB binds to nucleic acids and not to monomeric 
nucleotides. 
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Figure 18.  IsaB Does Not Bind Nucleotides.  Unlabeled competitors 
were added to EMSA reactions to determine their effect on the shift. 
EMSA reactions contain 270 pmol RNA and 480 pmol IsaB.  2.7 nmol of 
unlabeled competitors were added to reactions.  Lane 3, SSS, Lane 4, 
nuleotides, and Lane 5, yeast tRNA. 
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Figure 18.  IsaB Does Not Bind Nucleotides. 
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IsaB Binds to Nucleic Acids in the Low ηM Range. 
In order to determine the affinity of IsaB for dsDNA, ssDNA, and ssRNA, Surface 
Plasmon Resonance, SPR, was employed.  In this automated system, “bait” is immobilized 
onto a thin metal chip, and as the sample with the “target” is passed above the chip, the 
amount of target binding to bait can be measured. For our purposes, the bait used was  
dsDNA, ssDNA, and ssRNA, each of which was biotinylated to allow for immobilization 
onto a strepavidin-coated chip.  By flowing decreasing concentrations of IsaB over the 
chip and monitoring the strength of the interactions, the resonance units were collected and 
BiaCore Evaluation software was able to determine the dissociation (Kd) constant for the 
IsaB binding reactions. The sensogram shown in Figure 19a demonstrates that IsaB binds 
to the respective targets with significantly greater affinity then to the chip alone.  
Furthermore any observed non-specific binding was compensated for during analysis.  
However, due to the nature of the curve, no accurate stoichiometric analysis was able to be 
performed to due poor fit with modeling curves.  Figure 19b shows that IsaB binds 
slightly more avidly to dsDNA with binding occurring at 8.1x10-9 (8.1nM).  Therefore we 
can conclude that IsaB does bind all nucleic acids tested with similar affinity in the low 
nM range. 
 
Endogenous IsaB Contributes to Accumulation of eDNA on the Bacterial Surface. 
 We wanted to determine if deletion of isaB could have any significant effect on the 
accumulation of eDNA within S. aureus cultures.  In these assays, wild-type and ΔisaB 
strains were diluted from overnight cultures in TSB and 1% glucose was added to induce 
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Figure 19.  Affinity of IsaB for Nucleic Acids.  From SPR experiments, 
the affinity for dsDNA, ssDNA, and RNA was determined.  a) 
Representative sensogram, with non-specific binding subtracted, 
demonstrating the ability of decreasing concentrations of IsaB to bind to 
target.  b) Kd = dissociation constant, Ka = association constant.  Binding 
of IsaB to the bait is significantly above background binding, and exhibits 
a slightly higher affinity for ds DNA followed by ssDNA and RNA. 
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Figure 19.  Affinity of IsaB for Nucleic Acids. 
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Figure 20.  IsaB Aids in Accumulation of eDNA.  S. aureus strains 
Sa113, Sa113ΔisaB, 10833 and 10833ΔisaB were tested for their ability 
to bind exogenously added fluorescent eDNA.  Measurements were made 
using a fluorimeter and displayed as relative light units. Wildtype 
fluorescence levels were significantly higher with a probability value of 
p=0.006 for 10833 versus 10833ΔisaB and Sa113 versus Sa113ΔisaB 
(Student’s unpaired T test). 
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Figure 20.  IsaB Aids in Accumulation of eDNA. 
   10833        10833Δ isaB      SA113Δ isaB     SA113 
p=0.006 
p=0.006 
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isaB expression for four hours. After incubation in the presence of glucose to induce 
expression of isaB, fluorescently labeled SSS was added to cultures and incubated at 37℃ 
for 15 minutes before washing 3X to remove any unbound SSS DNA.  Surface-bound 
fluorescent DNA was quantified using a fluorimeter to determine relative light units.  As  
displayed in Figure 20, eDNA accumulated on the bacterial surface even in the absence of 
IsaB, but endogenously expressed IsaB lead to significantly greater accumulation of eDNA 
on the cell surface of S. aureus in both wild-type strains tested.  This finding demonstrates 
that while there may be other factors on the cell surface that interact with eDNA, IsaB does 
play a role. This suggests that binding of eDNA by IsaB is physiologically relevant. 
 
Discussion: 
The findings presented above show that IsaB is a novel extracellular nucleic acid 
binding protein.  While its nucleic acid binding ability did not exhibit sequence specificity, 
the interaction appeared to be dependent upon oligomeric nucleic acids, as monomeric 
dNTPs were unable to compete with nucleic acid binding. Furthermore, we found that the 
binding affinity of IsaB for its nucleic acid targets was in the low ηM range, which is 
indicative of strong binding. The lack of sequence specificity and the fact that IsaB binds 
strongly to any nucleic acid tested, suggests that IsaB may be interacting with the 
phosphate backbone of nucleic acids.  
To put the strength of the DNA binding activity into perspective, we compared the 
binding affinity of IsaB to affinities of previously characterized DNA binding proteins in 
S. aureus.  The affinity for the transcriptional regulators SarA and SarZ have both been 
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described for promoter sequences they are known to regulate, and were found to be in the 
low pM range which is far stronger binding than that observed by IsaB [108, 109].  
However these reports also found that each regulator exhibited binding in the low ηM 
range when binding to promoters they were not specific for (heterologous DNA) [108, 
109].  These studies suggest that the affinity of IsaB is in line with affinities of other DNA 
binding proteins interacting with DNA in a non-sequence-specific manner.  It is important 
to note that while it is unlikely that an extracellular nucleic-acid binding protein has 
sequence specificity, we cannot rule out the potential of an IsaB specific binding sequence, 
and if one were to exist, we would predict binding in the low pM range based upon the 
SarA and SarZ reports. 
The only published protein(s) known to be secreted by S. aureus that bind nucleic 
acids are the Thermostable nuclease(s) that were initially identified in the mid 1900’s [110-
113].  While it appears that many bacterial species actively secrete nucleases, there are 
only a few published reports of extracellular DNA-binding proteins.  Two extracellular 
DNA binding proteins from the literature are the Mycobacterium DNA-binding Protein 1 
(MDP1), and the Histone-like Protein A (HlpA), from M. tuberculosis and Streptococcal 
species, respectively.  It has been subsequently demonstrated that these proteins, while 
they bind DNA, are involved in binding to Glycosaminoglycans (GAGs), which aids in 
adhesion of bacterial cells to host tissues [114-116].  Furthermore, HlpA is capable of 
inducing a potent pro-inflammatory immune response [116].  This raises the possibility 
that, similar to other extracellular proteins with DNA-binding activity, IsaB may have 
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some other function.  Highly intriguing future studies would be to determine the ability of 
IsaB to promote inflammatory cytokine production and adherence to GAGs.    
It is also interesting to speculate how IsaB binding to DNA would affect Toll-like 
receptor 9 (TLR-9) activation which recognizes unmethylated CpG motifs found with high 
frequency in bacterial DNA [117-119].  Activation of signaling pathways through TLR-9 
leads to a significant cytokine production prompting a Th1 mechanism, leading to cellular 
based immune responses [117, 119].  Since S. aureus and other Staphylococci have been 
intimately associated with higher vertebrates throughout their evolution, perhaps IsaB 
could be playing a role in inhibiting TLR-9 activation, thus dampening the host immune 
response.  A mechanism can be envisioned wherein IsaB binds to bacterial CpG DNA, 
inhibiting TLR-9 recognition and the subsequent immune response.  Further studies of the 
DNA binding activity of IsaB and its involvement in pathogenesis could demonstrate 
previously unknown immune evasion mechanisms.
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CHAPTER 5 
 Role of IsaB in S. aureus Virulence 
 
 
Introduction: 
IsaB, one of four “immunodominant” proteins identified during sepsis, is described 
in the literature as a putative virulence factor [96,120]. Virulence factors are proteins or 
molecules secreted by pathogens to promote disease establishment and/or propagation in 
vivo but are not required for growth in vitro.  S. aureus has an immense arsenal of 
virulence factors that it skillfully regulates to cause significant morbidity and mortality 
worldwide.  Some of these virulence factors protect S. aureus from the host immune 
system by attacking cellular mediators (Panton-Valentine Leukocidin) or by hiding S. 
aureus from immune factors (Protein A).  Still others help S. aureus adhere to 
(MSCRAMMS and SERAMS) and invade (multiple Fibronectin binding proteins) host 
cells to help establish infection and promote dissemination through tissues (numerous 
super-antigens and toxins).  Finally a number of internal factors such as transcriptional 
regulators can be described as virulence factors due to their necessity for expression of 
external factors involved in pathogenesis (Sar family of transcriptional regulators).   
The immense number and diversity of virulence factors, and great amount of 
energy spent to make and regulate them, demonstrates how important they are for S. 
aureus to survive in vivo and to cause disease.  Due to their clinical importance, hundreds 
of studies have been performed in hopes of characterizing known or novel virulence 
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factors.  From these extensive studies there have been many simplified tools and 
techniques developed to demonstrate a role for a protein in the virulence of S. aureus.  
These techniques allow researchers to simulate in vivo conditions by exploiting model 
systems, such as the C. elegans killing model, or to directly determine the effect a protein 
has on protection from single factors such as AMPs or even ex vivo neutrophils.  We 
therefore sought to use a number of these previously described models to determine if IsaB 
does actually play a significant role in S. aureus virulence.   
 
Results: 
IsaB is not Required for Growth. 
In order to determine if deletion of isaB has deleterious affects on the growth of S. 
aureus, which would thus lead to bias in subsequent assays, growth curve experiments of 
wild-type and ∆isaB isogenic strains grown in normal culture conditions were performed.  
For these experiments S. aureus strain 10833 and 10833∆isaB were used.  Overnight 
cultures of these were diluted 1:100 in fresh LB or LBG and incubated with vigorous 
shaking at 37℃.  OD600 readings were taken at time-points 0, 2, 4, 6, 8, and 24 hours post-
dilution.  As Figure 21 depicts there was no decrease in growth rate or culture density 
observed in the ΔisaB strain. Similar experiments were performed in which media was 
supplemented with potentially harmful factors such as hydrogen peroxide, low pH, and 
sub-inhibitory concentrations of antibiotics. Even in the presence of these stressors there 
was no significant difference in bacterial growth observed. These data show that any  
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Figure 21.  Deletion of IsaB Does Not Affect Growth. Growth curve 
was performed to determine IsaBs affect on overall growth.  S. aureus 
strain Sa113 and Sa113ΔisaB were grown in LB or LBG and monitored 
at indicated time-points using OD600.  No obvious growth defect was 
observed in the deletion mutant. 
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Figure 21.  Deletion of IsaB Does Not Affect Growth.   
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difference in virulence observed is due solely to the presence or absence of IsaB, and not a 
difference in growth rate or fitness between the strains tested. 
 
IsaB Does Not Contribute to Virulence in C. elegans. 
Invertebrates can serve as rapid, tractable, and inexpensive models for the initial 
characterization of virulence factors [121].  One such model, C. elegans, has been 
developed and used to study the pathogenesis of S. aureus for a number of years [121-
123].  C. elegans has many properties inherent to vertebrate innate immune systems such 
as Toll-like receptors (TLRs), highly conserved signaling cascades, the production of 
reactive oxygen species, and also produce anti-microbial peptides or defensins [90, 121, 
122, 124-128] .  Due the significant overlap in innate and fundamental cellular targets, C. 
elegans killing assays have successfully been used to find or confirm virulence factors in S. 
aureus, E. faecalis, and S. pneumoniae, which are all important human pathogens [121, 
124].  
Upon ingestion of bacterial pathogens, which the worms attempt to avoid, the 
bacteria infect the intestinal epithelium of C. elegans and cause death by a variety of 
mechanisms, including blockage of the gastrointestinal tract by the formation of a bacterial 
biofilm, and by secretion of toxins [90, 122].  Proteomic studies of C. elegans during 
infection with pathogens have found that these nematodes sense infections and “mount” a 
protective response against pathogens, showing the ability to raise defenses similar to those 
found in humans [124].  Due to large amount of overlap with human innate immunity, 
previous proof of principle for identification of virulence factors, and the elegance and ease 
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of working with C. elegans, we sought to determine if IsaB, a putative virulence factor, 
could play a role in virulence in this model organism.   
In these experiments a protocol adapted from Begun et al, was employed [90]. 
Lawns of each S. aureus strain: wild-type, ΔisaB, or ΔisaB +isaB, were grown on LBG 
agar containing 5mg nalidixic acid/mL for 4-6 hours at 37ºC on plates.  Following initial 
growth of S. aureus, 10 nematodes were added per plate and placed at room temperature.  
The C. elegans fed upon the S. aureus, and this served as the mode of 
infection/inoculation.  We hypothesized that the wild-type 10833 and complemented S. 
aureus strains would be significantly more virulent than the ΔisaB mutant, and would lead 
to an increased rate of C. elegans killing.  C. elegans that failed to respond to touch were 
considered dead, and were tallied in order to calculate killing by each strain over a five-day 
period.  OP50, an avirulent strain of E. coli that the nematodes are fed in lab, was used as a 
negative control.  The results shown in Figure 22 suggest that while we did see increased 
death in nematodes grown on S. aureus strains, there was no significant difference in the 
rate of death between the three strains tested regardless of the presence or absence of IsaB.  
Therefore it is unlikely that IsaB contributes significantly to virulence in this model. C. 
elegans lacks an adaptive humoral immune response and most importantly lacks 
phagocytic cell lines, both of which are vital human host defenses against S. aureus so 
these results do not preclude a role for IsaB in virulence in higher organisms.  
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Figure 22.  C. elegans Killing Assay.  The nematode C. elegans was 
used a virulence model to determine if ΔisaB S. aureus was less virulent 
then wild-type.  Worms were grown on LBG plates feeding upon either 
10833, 18033ΔisaB or 10833ΔisaB+isaB.  Dead worms were counted 
everyday over five days.  No significant difference in virulence of the S. 
aureus strains were observed. 
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Figure 22.  C. elegans Killing Assay. 
   
 102 
 IsaB Does Not Increase Adherence or Invasion to Epithelial Cells. 
S. aureus has a large number of proteins involved in the adherence to and invasion 
of host cells and we wanted to determine if IsaB could be playing a role in either of these 
two mechanisms.  One piece of information that supported our hypothesis was a study  
done by Garzoni et al, which suggested through microarray analysis that isaB was 
upregulated approximately 5-fold 2 hours following internalization of S. aureus into 
human epithelial cells [49].  Using the human lung epithelial cell line A549 cells and both 
wild-type 10833 and 10833ΔisaB strains, we performed experiments to determine whether 
IsaB has a role in either adherence or in antibiotic stimulated invasion. 
Briefly, bacterial cells were washed in PBS and added to confluent wells of A549 
cells.  For adherence assays, the bacteria and A549 cells were co-cultured for 1 hour before 
nonadherent bacteria were removed by washing with PBS.  Adherent bacteria were 
collected by lysing the A549s with PBS containing saponin, and were plated for the 
enumeration of CFUs.  For invasion assays, a similar procedure was performed as for 
adherence, except after the initial 1 hour co-culture, media was replaced with media 
containing gentamicin and incubated for 1 hour to kill all extracellular cells.  The 
gentamicin was removed by washing with PBS, and invasive cell counts were enumerated 
as CFUs.  As shown in Figure 23 there was no difference observed in the amount of 
adherence or invasion between the two strains, suggesting that IsaB does not likely play a 
significant role in either of these two pathways. 
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Figure 23.  IsaB Does Not Increase Adherence or Invasion.  IsaB was 
analyzed for its ability to aid in S. aureus adherence or invasion into 
A549 lung epithelial cells.  S. aureus strains Sa113 and Sa113ΔisaB 
were induced in TSBG prior to co-culture with A549 cells.  Adherence 
was assayed after 1 hour co-culture.  For invasion, non-invasive cells 
were killed with 1hr gentamycin treatment.  Adhesion and invasion were 
determined by lysins of A549 cells and plating for CFUs.  Percentages 
were determined by comparing inoculum to adherent or invasive.  
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Figure 23.  IsaB Does Not Increase Adherence or Invasion. 
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IsaB Does Not Increase S. aureus Survival in Whole Blood.  
As discussed above, IsaB was first characterized by its observed immunogenicity 
following septicemia, suggesting that it is actively expressed during these systemic blood 
infections.  Furthermore, as shown in Chapter 3, isaB expression is induced approximately 
5 fold upon exposure to either plasma or serum.  This information led us to hypothesize 
that IsaB could play an important role in S. aureus survival in whole blood, which 
inherently consists of numerous adverse or bactericidal components, such as complement 
and antibodies.    
To address this, overnight cultures of S. aureus 10833 and 10833ΔisaB were grown 
in TSBG.  Cultures were diluted 1:10 in pooled human blood and incubated up to 4 hours 
with samples taken at 30 minutes, 2 and 4 hours.  Samples were sonicated 2X separated by 
a wash with sterile water between, which was done in order to break up S. aureus 
aggregates and to lyse red blood cells to allow for accurate CFU counts.  CFUs obtained 
were then used to determine the amount of survival observed.  As shown in Figure 24 
there was no significant decrease in percent survival in the ΔisaB mutant compared to 
wild-type demonstrating that IsaB does not affect survival in whole blood culture.  
 
IsaB Does Not Protect Against Neutrophil Mediated Killing. 
Neutrophils are considered to be the body’s primary defense against S. aureus.  
Therefore, S. aureus has a number of virulence factors it employs to evade neutrophil-
mediated killing.  There are a number of assays used to assess the protective role virulence 
factors have in circumventing neutrophil mediated killing through phagocytosis.
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Figure 24.  IsaB Does Not Protect S. aureus in Whole Blood.  To 
determine if IsaB could increase S. aureus survival in whole blood strains 
10833, 10833ΔisaB, Sa113, and Sa113ΔisaB were incubated in freshly 
collected whole human blood.  Percent survival was determined by CFUs 
comparing samples treated with blood to untreated.  ΔisaB had no affect 
on S. aureus ability to adhere to or invade A549 epithelial cells. 
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Figure 24.  IsaB Does Not Protect S. aureus in Whole Blood. 
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One of the most commonly used are opsonophagocytic assays that can be easily modified 
to provide different information, i.e. evasion of phagocytosis or survival after phagocytosis 
[91, 129, 130].  Because S. aureus causing septicemia had to continuously subvert these 
killing mechanisms to establish systemic infection, and because isaB was induced in 
response to serum, and putatively in response to neutrophils and AMPs, we hypothesized 
that IsaB could play a pivotal role in S. aureus evasion of neutrophil mediated killing. 
We therefore used a protocol adapted from Corbin et al to assess the ability of IsaB 
to protect S. aureus from neutrophil mediated killing [91].  Briefly, cultures of S. aureus 
strains 10833 and 10833ΔisaB were grown overnight in TSBG.  The bacterial cells were 
then pre-opsonized with 50% human serum, which allowed for complement and antibody 
deposition that greatly increases the efficiency of phagocytosis.  2x107 human neutrophils 
were co-cultured with the pre-opsonized bacteria at an MOI of 1 for 2 hours.  Neutrophils 
were then lysed with saponin, samples were sonicated and plated for CFUs.  Figure 25 
shows the results from this assay. There was a slight decrease in survival in the absence of 
isaB, but this did not reach statistical significance.  These data suggest that IsaB does not 
significantly protect from phagocytosis by human neutrophils. 
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Figure 25.  Evasion of Neutrophil Mediated Killing.  To determine 
IsaBs role in protection of S. aureus from opsonophagocytosis, pre 
opsonized 10833 and 10833ΔisaB were co-cultured with human 
neutrophils at an MOI of 1.  CFUs were used to compare percent survival 
from CFUs of pre-opsonized input.  No significant difference in survival 
from phagocytosis was observed after 2 hours of co-culture. 
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Figure 25.  Evasion of Neutrophil Mediated Killing. 
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IsaB Protects S. aureus Against NETs 
 While neutrophils are excellent phagocytes, they are also capable of secreting 
neutrophil extracellular traps, NETs, which occurs through “neutrophil suicide” [17, 19, 
92, 131, 132].  Formation of NETs is induced in response to a number of threatening 
stimuli, including bacteria, and are made up of secreted neutrophil DNA along with its 
bound histone proteins, and a number of Antimicrobial Peptides and Proteins [92, 131, 
132].  In vivo NETs can either kill S. aureus, which is likely due to the increased local 
concentrations of antimicrobial agents, or they can trap the bacteria and prevent their 
spread further into host tissues, also allowing other effectors and cells to be recruited [92, 
131, 132].  Due to ability of IsaB to bind eDNA, which is the main component of NETs, it 
was intriguing to observe whether deletion of isaB had an affect on S. aureus survival 
following incubation with NETs.  Neutrophils were isolated, and secretion of NETs was 
induced using PMA following the protocol from Jann et al [92].  Stationary phase 10833 
and 10833ΔisaB strains were then co-cultured with the NETs for 30 minutes to allow for 
killing.  Figure 26 shows the percent survival of wild-type and ΔisaB strain.  Excitingly 
we found that the wild-type strain survived NET killing 2.5 fold better than deletion 
mutant strain, which was statistically significant with a p-value of 0.02.  These findings 
indicate that IsaB plays a significant role in protecting S. aureus from NETs. 
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Figure 26.  IsaB Significantly Protects S. aureus From NETs.  
Neutrophil Extracellular Traps, NETs, are an alternative form of killing 
by neutrophils.  To determine if IsaB played a significant role in S. 
aureus evasion of these NETs S. aureus strain 10833 and 10833ΔisaB 
were co-cultured with NETs secreted by freshly isolated human 
neutrophils.  S. aureus strains were grown overnight and then used at an 
MOI of 0.01 to  infect Neutrophils induced to secret NETs.  Bacteria 
were centrifuged onto the NETs and co-cultured for 30 min.  Samples 
were then sonicated and used for CFU enumeration.  Percent survival was 
determined by comparing CFUs from NETs to CFUs of input.  The data 
show that deletion of isaB had a significant and negative impact on S. 
aureus ability to survive NETs exposure, p = 0.02.  Student’s t-test was 
used for statistical analysis.   
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Figure 26.  IsaB Prevents Killing By NETs. 
   
 114 
IsaB Significantly Increases Survival Following Treatment With Antimicrobial 
Peptides. 
Antimicrobial peptides or AMPs, are highly cationic small peptides that have been 
found to be potent bactericidal innate immune components.  Interestingly microarray data 
from Herbert et al, revealed that isaB is upregulated by the two-component system GraRS, 
which plays a major role in S. aureus resistance to AMPs [32].  Furthermore, one of the 
hypothesized mechanisms of NET mediated killing is the NETs ability to sequester AMPs 
and locally increase their concentration, allowing the AMPs to interact more intimately 
with the bacteria.  Therefore, we hypothesized that IsaB, which is highly cationic, could 
aid in the repulsion of the cationic AMPs from the cell surface of S. aureus. 
Because it was unknown how IsaB could affect individual AMPs four were chosen 
for study based on their previous validated potency against S. aureus; HNP1, HBD3, 
HBD2, and Buforin [29, 30, 133].  The chosen AMPs were mixed together and used to 
treat either wild-type or ΔisaB strains.  Briefly, overnight cultures of 10833 and 
10833ΔisaB were grown in LBG.  These stationary phase cultures were then diluted 1:100 
in PBS containing 2.4µg/ml of each AMP and incubated together for 2 hours before plating 
for CFUs.  As shown in Figure 27, deletion of IsaB significantly decreased S. aureus 
survival compared to wild-type in response to AMP treatment.  The wild-type survived 
approximately 4 fold better than the isaB deletion mutant strain with p = 0.001.  Therefore 
IsaB significantly protects S. aureus from AMPs.   
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Figure 27.  IsaB Protects S. aureus From AMPs. To determine IsaBs 
ability to protect S. aureus from AMPs, S. aureus strains 10883 and 
10833ΔisaB were treated with a combined mixture of AMPs: HNP1, 
HBD2, and HBD3.  After 2 hour treatment, samples were plated for 
CFUs.  Percent survival was determined by comparing untreated to AMP 
treated samples.  IsaB was found to significantly increase S. aureus 
ability to survive AMP exposure, p = 0.001.  Student’s t-test was used for 
statistical analysis. 
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Figure 27.  IsaB Protects S. aureus From AMPs. 
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Discussion: 
 From the above studies we found that IsaB does not appear to have a significant 
role in growth, adherence, invasion or survival in whole blood.  However we have shown 
that IsaB is in fact a virulence factor, one that significantly protects S. aureus from 
Antimicrobial Peptides and Neutrophil Extacellular Traps.  These findings are extremely 
exciting as they lend significant clinical relevance to our studies and show that as 
hypothesized, IsaB is an important and novel virulence factor of S. aureus.  It is important 
to note that the significant role IsaB has in evasion of AMPs and NETs is likely 
intertwined and due to the same phenomenon.   
As described above it is hypothesized that NETs have a high concentration of 
AMPs associated with them and that it is the AMPs in the NETs that are responsible for 
bactericidal activity.  Furthermore, the neutrophils in our assays were inactivated during 
co-culture with S. aureus by the addition of cytochalsin D to the media, thus showing that 
it is NET killing and not a combination of NET and phagocytosis-mediated killing.  The 
fact that IsaB had a significant role in evasion of NET killing strongly suggests that IsaB 
acts in a physiologically relevant manner, supporting the data from the more extrapolated 
AMP killing assays.   
While IsaB played a significant role in these two assays, we found no significance 
in its ability to protect against phagocytosis or promote killing in C. elegans.  In the case of 
the opsonophagocytic assay, many AMPs are likely kept sequestered within the neutrophil 
where they have an active role in the phagolysosome.   Additionally if AMPs were 
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secreted they may not have reached a great enough local concentration to significantly 
inhibit/kill the bacteria.  Also, the opsonophagocytic assay is a much more complex assay 
in which S. aureus has many previously described virulence factors which could mask the 
significance of IsaB.  As to why no significant role for IsaB was observed in the C. 
elegans, it is likely due to many of the same reasons given for evasion of neutrophil 
mediated killing.  However, it could also be argued that IsaB is a protective mechanism 
and while it helps the S. aureus survive in vivo or within the C. elegans, it does not appear 
to directly target or affect the host on its own, and thus it does not significantly affect 
killing in this assay.  However it is interesting that while there was no significant 
difference between the wild-type, complemented and ΔisaB strains, the overall trend 
suggested reduced killing of the nematodes by the ΔisaB mutant; that the wild-type killed 
more, and that the complemented strain exhibited the highest killing rate, however there 
was great variability within each experiment and between repeats.  Therefore IsaB could 
play a role in this model that might be observed if the variability in the assay was somehow 
decreased.    
As discussed above, one of the common ways that pathogens including S. aureus 
subvert AMPs is through extensive modification of their cell surfaces to help neutralize the 
overall negative charge of their surface.  It is therefore intuitive to postulate that IsaB, 
which is highly cationic and associated with the cell surface, would have a significant 
effect on repelling AMPs, thus not allowing them to bind and perform their bactericidal 
activities.  A second mode of action could relate to the ability of IsaB to bind to eDNA.  
AMPs have been found to interact with NETs that are primarily composed of DNA.  It 
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could therefore be possible that IsaB binding to eDNA acts as a decoy causing the AMPs 
to bind to it instead of the bacterial surface.  We strongly believe that IsaB is likely acting 
in one of these two functions and that IsaB is not playing a role in degradation of the 
AMPs as we have not observed any proteolytic or enzymatic activity with purified protein.  
From these studies we now know that IsaB is a novel AMP evasion virulence 
factor, which can account for its immunogenicity/expression in vivo.  Due to its ability to 
protect S. aureus from AMPs, it strongly suggests that IsaB is an important factor not only 
in septicemia but potentially all disease manifestations of S. aureus as AMPs are found 
throughout the body.  Furthermore, if IsaB is expressed in response to serum, AMPs and 
neutrophils, it would be expressed during all acute S. aureus disease manifestations,  
making IsaB an extremely attractive antibody therapeutic target or potential vaccine 
candidate. 
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CHAPTER 6 
 Role of IsaB in S. aureus Biofilms 
 
  
Introduction: 
 There is a well-established precedent for the role of extracellular DNA within 
bacterial biofilms.  eDNA has been found to be a major biofilm matrix component in many 
Gram-positive and Gram-negative pathogens such as S. epidermidis, N. meningitidis, L. 
monocytogenes, S. mutans, E. faecalis, and P. aeruginosa [15, 134-138].   However, until 
recently, it was believed that the S. aureus biofilm was made up predominantly of PNAG.  
Several studies performed by Dr. Kenneth Bayles (University of Nebraska, Omaha, NE) 
have implicated eDNA in the formation and maintenance of the S. aureus biofilms [66, 67, 
139].  These studies have shown that under certain conditions, S. aureus undergoes 
autolysis/lysis, releasing genomic DNA, which is then used as a matrix component for the 
developing biofilm, a system similar to those in other bacterial species that utilize eDNA in 
their biofilm matrices [15, 66, 67, 136-139].   
Because it is unknown how the eDNA is incorporated into the matrix, we 
hypothesized that IsaB could be playing an important role in biofilm formation.  One could 
rationalize that IsaB, as an extracellular nucleic acid binding protein, could play a 
significant role in either the incorporation of eDNA into the biofilm, or in promoting 
adherence of the bacterial cells to the biofilm matrix.  Therefore the studies that follow 
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were performed with the intent of determining the role of IsaB in biofilm formation of S. 
aureus. 
 
Results: 
isaB Is Not Differentially Expressed Between Biofilms and Planktonic Cultures. 
 We hypothesized that if IsaB played a role in biofilm formation then transcription 
of the isaB gene would be elevated in biofilms with respect to planktonic cultures. A study 
by Resch et al, suggested that isaB was upregulated approximately 3-fold in 24, and 48 
hour biofilms compared to planktonic [96].  Briefly, overnight wild-type cultures were 
diluted 1:10 in TSBG and added to either 96-well plate, or into 10mls TSBG.  These 
cultures were grown overnight, and the following day the media was removed and replaced 
with fresh TSBG and incubated for 2 hours prior to collection for RNA extraction.  Using 
RT-PCR, no difference was observed in the expression of isaB between the two modes of 
growth as shown in Figure 28.  Therefore, under our standard laboratory conditions there 
was not a differential regulation in isaB expression between biofilms and planktonic. 
 
IsaB Negatively Impacts Biofilm Formation. 
 The use of confocal microscopy is advantageous for the direct visualization of S. 
aureus biofilms because it allows for estimation of biofilm depth and architecture.  
Therefore, biofilms of either wild-type or ΔisaB were grown under static conditions in 6-
well plates overnight at 37℃.  The biofilms were washed in PBS and stained with 
BacLight Live/Dead, which imparts green fluorescence to viable bacteria and red to dead  
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Figure 28.  isaB is Not Differentially Expressed.  To determine if isaB 
is expressed more or less in the biofilm mode of growth RT-PCR was 
done.  
S. aureus 10833 was grown as either a biofilm or planktonic culture in 
TSBG overnight.  The cultures were then “fed” with fresh TSBG for 2 
hours to stimulate metabolic activity.  RT-PCR for isaB expression was 
performed.  No difference was observed in isaB expression between the 
two modes of growth.  All samples were normalized to their 16s rRNA ct 
values. 
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Figure 28.  isaB is Not Differentially Expressed in Biofilms. 
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bacteria.  The biofilms were visualized directly by confocal microscopy.  We had 
hypothesized that IsaB would likely have a positive affect on biofilm formation and 
therefore when isaB was deleted a decrease in biofilm formation would be observed.  
However, as shown in Figure 29a, deletion of isaB appeared to have a positive affect on S. 
aureus biofilm, countering the hypothesis. 
 To confirm the visualized increase of biofilm in the deletion mutant, and to get 
quantitative data, the 96-well microtiter biofilm plate assay was utilized.  In these 
experiments, overnight cultures of wild-type or ΔisaB were diluted 1:10 in TSBG, added to 
each well and grown overnight at 37℃.  The following day the biofilms were washed in 
PBS to remove any non-adherent cells, stained with safranin, and dried.  Safranin was 
solubilized using 33% acetic acid and read on a plate reader at OD564.  As shown in Figure 
29b, these experiments confirmed the previously seen increase, which was equivalent to an 
approximately 12% increase in biofilm compared to the wild-type strain.  These 
experiments suggest that under the conditions tested and for the strain tested, not only does 
IsaB not augment biofilm formation, it may actually hinder it in some way. 
 
The Negative Effect of IsaB on Biofilm Formation Depends upon Culture Conditions. 
 To determine if IsaB negatively affected biofilms in all growth conditions and in 
multiple wild-type strains, biofilms were grown in a variety of medias.  The biofilms were 
grown as described above, however they were grown in LB, LBG, BHI, BHIG, TSB or 
TSBG+NaCl.  TSBG was supplemented with 3.25% NaCl because a recent publication  
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Figure 29.  IsaB Decreases Biofilm Formation.  To determine if IsaB 
was significant in eDNA biofilm incorporation biofilm assays were 
performed.  S. aureus strain 10833 and 10833ΔisaB were grown in 
TSBG. a) For confocal microscopy, biofilms were grown in a 6-well 
plate and stained with Live/Dead stain prior to microscopy.  b)  96 well 
biofilm microtiter plate assay was used to get quantitative data about the 
observed increase in biofilm formation.  Biofilms were stained with 
safranin, solubilized with acetic acid and read at OD564.  IsaB produced 
significantly more biofilm than wildtype p= 0.004.  Student’s t-test was 
used for statistical analysis. 
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Figure 29.  IsaB Decreases Biofilm Formation. 
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suggested that growth in either glucose or glucose + NaCl could induce biofilm formation 
[61].  A representative photo of the biofilm plate before solubilization with acetic acid is  
shown in Figure 30a.  The graph in Figure 30b, shows the quantitative data obtained from 
the plate reader.  As the graph shows, under most conditions tested there is no observed 
effect of deletion of isaB.  However, when both wild-type strains were grown in LBG the 
same significant increase of biofilm formation in the ΔisaB strains was observed.  These 
findings suggest that IsaB interferes with biofilm formation only under certain inducing 
conditions.   
 
IsaB Does Not Affect the Role of eDNA in Biofilms. 
DNAse has been used as a tool to assess the role of eDNA in biofilms [66, 86]. We 
therefore used a similar assay to determine the extent of eDNA biofilm incorporation 
between the wild-type or ΔisaB strain.  For these experiments, biofilms were grown in 
TSBG as previously described.  Following overnight growth, the cultures were either left 
untreated, or treated with 2.5 Units of DNAse for 4 hours prior to washing, staining, and 
reading with the plate reader.  Figure 31a is a representative microtiter plate demonstrating 
the extent of visual DNAse degradation.  Figure 31b shows the data from the plate reader 
expressed as % intact biofilm following DNAse treatment.  As this graph shows, there was 
not a significant difference observed in the amount of DNAse degradation between the 
wild-type or ΔisaB strains tested.  Suggesting that IsaB does not significantly modulate the 
amount of eDNA within the biofilm matrix. 
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 Figure 30.  IsaB Only Affects Biofilms Under Specific Growth 
Conditions.  To observe how consistent the increase in biofilm formation 
occurred when isaB was deleted biofilms were grown in a wide variety of 
media with different supplementation.  a) Representative image of 
stained biofilms prior to solubilizing.  b) quantittative results from 
biofilms using the plate reader.  ΔisaB biofilms grown in LBG for both 
displayed significantly greater biofilm formation p=0.005 (10833) and 
p=0.0003 (Sa113) than parental strains. Student’s t-test was used for 
statistical analysis. 
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Figure 30.  IsaB Only Affects Biofilms Under Specific Conditions. 
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Figure 31.  IsaB Does Not Play a Role in eDNA Incorporation.  To 
determine if IsaB was able to change the amount of eDNA in the biofilm 
matrix DNAse sensitivity assays were performed.  S. aureus strains 
10833, 10833ΔisaB, Sa113, and Sa113ΔisaB were grown as biofilms in 
TSBG in a 96 well microtiter plate.  Biofilms were then DNAse treated 
with 2.5U DNAse for four hours.  a) Representative image of stained 
biofilms following DNAse treatment.  b) Graph of quantitative data from 
OD564.  Statistical analysis was performed using the Student’s t-test.  No 
Statistically significant difference was observed as % degradation by 
DNAse. 
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Figure 31.  IsaB Does Not Play a Role in eDNA Incorporation. 
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IsaB Does Not Affect Biofilm Formation in Serum. 
  Evidence suggests that IsaB is expressed during septicemia. Therefore, we 
hypothesized that IsaB may play a more important role in biofilm formation under 
physiologically relevant conditions.  Because biofilms have been found to be important 
contributing factors in a number of diseases, we wanted to determine if IsaB could promote 
biofilm formation in various concentrations of serum.  Aside from being more relevant to 
human disease, Figure 8 shows that isaB is induced by exposure to serum.  Therefore 96-
well biofilm microtiter assays were performed as described above, however instead of 
bacterial growth media, 1:2 dilutions of serum diluted in TSBG were used.  Figure 32 
shows the results from reading at OD564nm, and as can be seen, there is no difference 
observed between wild-type or ΔisaB strains at any concentrations of serum tested.  
 
Discussion: 
 
We hypothesized, due to the ability of IsaB to bind DNA and to increase the 
amount of eDNA accumulated on the cell surface, that IsaB would have a significant role 
in biofilm formation.  Through our studies, it was determined that IsaB, surprisingly, had a 
negative impact on biofilm formation (under certain conditions) in contrast to our expected 
result.  Biofilms were also grown in various concentrations of human serum in the hopes 
that isaB could potentially augment biofilm formation under conditions that most closely 
mimic human disease.  However, we again observed that IsaB had no significant affect on 
biofilm formation in human serum. 
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  Figure 32.  IsaB Does Not Affect Biofilm Formation in Serum.  To 
look at IsaBs role in biofilm formation under more physiologically 
relevant conditions, biofilms were grown in human serum.  S. aureus 
strains 10833 and 10833ΔisaB were grown in 100%, 50%, 25%, 12.5% 
and 6.25% human serum diluted in TSBG.  Biofilms were stained with 
safranin and quantitative data was obtained by OD564.  No significant 
difference in Biofilm formation was observed in either wild-type or 
ΔisaB strain. 
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Figure 32.  IsaB Does Not Impact Biofilm Formation in Serum. 
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It is important to note, that while the increase in biofilm observed with the ΔisaB 
was statistically significant (possibly due to a large n), it is not clear that this slight 
increase is physiologically relevant. However, the increase could be due to binding of 
eDNA by IsaB, which could block binding sites used in biofilm formation and attachment.  
Why would IsaB not be involved in augmenting biofilm formation by aiding in the 
incorporation of eDNA?  Perhaps IsaB could be involved in biofilm formation under 
growth conditions that were untested, or another un-characterized protein with redundant 
function could be masking the deletion.  Either way, we have shown that IsaB, while 
expressed in biofilms (at levels similar to planktonic), does not augment biofilm formation 
in the S. aureus strains tested. 
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CHAPTER 7 
Structural Analysis of IsaB 
 
  
Introduction: 
We have found that IsaB binds to nucleic acids in a non-specific manner and 
protects the bacteria from antimicrobial peptides and NET-mediated killing. However, 
IsaB does not have significant similarity, at least at the amino acid sequence level, to other 
proteins of known function (or even to hypothetical proteins from other Genera). 
Therefore, we do not know whether it functions in a manner similar to other nucleic acid-
binding proteins or other proteins involved in AMP-evasion.  Furthermore, we do not 
know whether IsaB has an additional primary metabolic function. We attempted to use 
protein structure/function prediction programs, such as I-TASSER Online (available at 
http://zhanglab.ccmb.med.umich.edu/I-TASSER/ ) to predict IsaB function and structure. 
However in silico analyses were unable to confidently predict a likely structure or 
function, therefore experimental methods were employed [140].   
To date there are a number of techniques used to determine the 3-dimensitional 
structure of proteins, two of the most commonly used are X-Ray Crystallography and 
Nuclear Magnetic Resonance [141-143].   X-Ray Crstallography is considered to be the 
gold-standard used for protein structure determination.  This technique requires successful 
formation of a protein crystal, which is then subjected to a X-Ray beam [142].  The protein 
structure is then determined by the amount and angle of X-ray beam diffraction.  Unlike X-
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ray Crystallography, NMR does not require crystal formation for successful structure 
determination allowing for more rapid analysis.  In NMR the protein is analyzed in 
solution during NMR, and is subjected to a large magnetic field.  The magnetic resonance 
of individual atoms in each aa are assigned and used to determine the proximity to other 
amino acids which subsequently reveals the folding structure [142-144]. While NMR can 
produce accurate structural information more rapidly then X-Ray Crystallography, its use 
is often hindered by strict size constraints as it has only been used to identify structure in 
molecules under 30 kDa, and often requires labeling with isotopes [141-143].   
The objective of this study was to determine the structure and localization of IsaB 
in an attempt to better understand its function. We found that IsaB is an extracellular 
protein that is largely associated with the bacterial cell surface. We purified protein for use 
in x-ray crystallographic analysis by our collaborators Drs. Martin Safo and Faik Musayev, 
but sufficient crystals for analysis could not be produced. We then purified protein for 
Nuclear Magnetic Resonance analysis in collaboration with Dr. David Williams to 
determine the definitive structure of IsaB.   
 
Results: 
IsaB in Staphylococci 
 isaB has been annotated in multiple S. aureus genomes 
(http://www.ncbi.nlm.nih.gov/nuccore), allowing us to use BLAST to determine the 
distribution of IsaB throughout the S. aureus genomes [145].  As shown in Figure 33, IsaB 
was highly conserved between all annotated S. aureus genomes.  Interestingly, we found 
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that IsaB homologues were in all sequenced Staphylococcal species with varying degrees 
of identity Figure 33.  However, beyond the staphylococci, IsaB does not appear  
to have any significant similarity to any known proteins.  Therefore, IsaB appears to be 
specific to this genus. 
 
m-IsaB Predictions. 
 Prediction software was used to determine where the signal peptide sequence 
would be cleaved, and what the mature protein would “look” like.  The SignalP 3.0 
software (available at http://www.cbs.dtu.dk/services/SignalP/), was used to determine 
where a Gram-positive signal peptidase would cleave IsaB, the results are shown in Figure 
34 [146].  As the data and graph show, signal cleavage is predicted, with 97% probability, 
to occur between position 36-37, cutting at the sequence 5’ AQA-AI  3’.  Thus the most N-
terminal aa of m-IsaB is an alanine.  The predicted m-IsaB was then analyzed by the 
Expasy online tool (available at http://www.expasy.ch/cgi-bin/protparam), and was 
predicted to be 139 aa in length, with a molecular weight of ~15.8 kDa, and a theoretical pI 
of 9.66 [147].  
  Next Emboss (available at http://www.ebi.ac.uk/Tools/emboss/pepinfo/ ) was used 
to visualize the types of aa throughout the protein, as shown in Figure 35, which was 
useful to determine where pockets of positive and negative charges, along with polar vs  
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Figure 33.  Homology of isaB in Staphylococci.  Using BLAST search 
IsaB has been found in all currently sequenced S. aureus strains.  This 
chart depicts the ranges of homology between IsaB homologs.  Putative 
IsaB genes have been found in all genomes of sequenced Staphylococci 
with varying degrees of similarity. 
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Species Identity Similarity
S. aureus 82-100% 93-100%
S. epidermidis 42-55% 63-76%
S. haemolyticus 48% 65%
S. capitis 39-47% 63-68%
S. hominis 46% 61%
S. warneri 37% 59%
S. saprophyticus 35% 56%
S. carnosus 31% 50%
Figure 33.  Sequenced Staphylococcus Species Containing 
Putative IsaB 
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Figure 34.  Predicted Singal Peptide Cleavage Site.  Using SignalP 3.0 
prediction server we determined that IsaBs signal peptide sequence is 
most likely cleaved between aa 36-37, with a probability of 0.97.  Bolt 
indicated signal peptidase cleavage on the peptide backbone of IsaB.  The 
mature 5’ end is an Alanine. 
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# Most likely cleavage site between pos. 36 and 37: AQA-AI 
SequencePrediction: Signal peptideSignal peptide 
probability: 1.000Max cleavage site probability: 
0.973 between pos. 36 and 37 
MNKTSKVCVAATLALGTLIGVTVVENSAPTSKQAQA-AITPYYTYNGYIGNN 
 
p = 0.973 
N-Terminal Signal Peptide 
Sequence 
5’ m-IsaB 
Figure 34.  Predicted Signal Peptide Cleavage 
Site. 
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Figure 35.  Distribution of Amino Acids in IsaB.  Using the Emboss 
prediction server we were able to analyze the aa characteristics 
throughout IsaB.  There do not appear to be any significant patches of aa 
of a particular type or charge throughout the backbone.   
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Figure 35.  Distribution of Amino Acids in IsaB 
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nonpolar aa [148].  The predicted hydrophathy chart was also obtained from Emboss and 
as shown in Figure 36, m-IsaB is predicted to be mainly hydrophilic (hydropathy < 0) 
aside from a hydrophobic patch at the C-terminus.  It is therefore likely that the 
hydrophobic patch is sequestered within the folded protein, while strongly hydrophilic 
areas are predicted to be exposed on the surface of the folded protein.  From these 
predictions, we now know the size and aa sequence of m-IsaB, and many of the 
characteristics governed by its aa sequence. 
 
IsaB is an Anchorless Protein. 
As mentioned previously, BLAST analysis of IsaB showed that IsaB had a Gram-
positive signal peptide sequence, interestingly it did not predict the presence of a 
conserved Gram-positive cell-wall anchoring motif, commonly called a LPXTG motif.  
This motif allows for bacterial sortase genes to covalently anchor secreted proteins to the 
peptidoglycan layer, thus keeping them attached to the cell surface and preventing release 
beyond the cell [7]. 
Therefore, we wanted to ensure that the cell-surface association of IsaB was in fact 
independent of sortase.  To answer this question, a srtA deletion mutant was used for 
western blot analysis.  Overnight cultures of S. aureus strains 502, 502ΔsrtA, and 
10833ΔisaB were grown in TSBG, and cell surface associated proteins were extracted.  As 
shown in Figure 37, deletion of S. aureus srtA gene had no observed effect on IsaB 
association with the cell surface.  This experiment confirms that association of IsaB with 
the surface of S. aureus is independent of Sortase A. 
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Figure 36.  Hydropathy Chart of IsaB (Kyte-Dolittle).  Using 
Emboss prediction server, we obtained m-IsaBs proposed hydopathy 
chart.  Most of the protein appears to be hydrophilic (< 0) however there 
is a hydrophobic patch on the carboxy terminus which would likely be 
folded within the mature secreted protein. 
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Figure 36.  Hydropathy Chart of IsaB (Kyte-Dolittle). 
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Figure 37. IsaB Surface Association is Independent of Sortase A.  To 
validate the prediction that IsaB is anchorless and to determine if IsaB 
could be binding to an anchored protein, a Sortase A deletion mutant was 
used.  S. aureus strains RN450 and RN450ΔsrtA were grown overnight 
in TSBG.  Cell samples were collected and screened with anti IsaB 
antibody.  No difference in the amount of IsaB was detected between the 
two strains. 
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Figure 37. IsaB Surface Association is Independent of Sortase A. 
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Lipoteichoic Acid Does Not Tether IsaB to the Cell Surface. 
 The histone-like protein of Streptococcus species was mentioned earlier because it 
is one of the few published extracellular DNA-binding proteins.  Another similarity that 
HlpA shares with IsaB is that it also an anchorless cell surface associated protein.  A study 
by Boleij et al, showed that HlpA associates with the cell surface via binding to 
lipoteichoic acid (LTA), which is found in many Gram-positvie bacteria, including S. 
aureus [115, 149].  Furthermore, teichoic acids have been shown to be significant defenses 
against AMPs and therefore IsaB binding to teichoic acids could have synergistic activity.  
Therefore we wanted to determine if IsaB was interacting with surface exposed teichoic 
acids.   
We obtained a ΔtagO strain that is not able to secrete wall teichoic acids (WTA), 
however this mutant will still secrete LTA. To address the ability of IsaB to bind to WTA 
thus allowing it to associate with the cell surface, western blot analysis was used to 
compare IsaB cell surface association in the wild-type and ΔtagO.  Overnight cultures of S. 
aureus strains 10833, 10833ΔtagO and 10833ΔisaB were grown in TSBG.  Cells were 
collected by centrifugation and cell surface proteins were extracted with SDS.  As the blot 
in Figure 38 shows IsaB was detected in the wild-type and ΔtagO strains in similar 
amounts.  These findings show that IsaB cell surface association was independent of WTA 
expression.  Therefore, wall-teichoic acids do not contribute to IsaB binding to the cell 
surface. 
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Figure 38.  Teichoic Acid Does Not Tether IsaB to Surface.  There is 
precedence for anchorless proteins to bind to LTA or WTA in order to 
associate with the cell surface.  We obtained a WTA (tagO) deletion 
mutant and compared IsaB cell surface association with its parental 
strain.  S. aureus strains 10833, 10833ΔtagO, and 10833ΔisaB were 
grown overnight in TSBG and cells were collected for western analysis 
using our anti-IsaB antibody.  No difference in IsaB amount was 
observed between the wild-type and WTA deletion mutant. 
   
 152 
 
Figure 38.  Teichoic Acid Does Not Tether IsaB to Surface. 
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IsaB Cell Surface Association is Independent of Neutral Phosphatase. 
 There have been some reports in the literature describing anchorless protein 
association with the cell surface.  One such report by Flock and Flock showed that Eap, an 
important MSCRAMM is a secreted anchorless protein which re-binds to the cell surface 
by binding to Neutral Phosphatase [150].  Interestingly, NPase is also an anchorless cell 
surface associated protein [150, 151].  Intrigued by this study, we looked at the dependence 
of IsaB surface association in wild-type, deletion mutant (ΔnPase), and complemented 
strain (ΔnPase+nPase).  Using overnight cultures grown in TSBG, western blot analysis 
was performed as previously described.  As Figure 39 shows, levels of IsaB are constant 
in both the supernatant and cell surface extracts in samples irrespective of NPase status.  
Therefore, NPase does not aid in the ability of IsaB to re-associate with the cell surface. 
 
X-ray crystallography 
In order to get real answers about the structure of IsaB, we initially collaborated 
with Dr. Martin Safo and Dr. Faik Musayev at the VCU Center for Biologic Complexity to 
perform crystallography analysis.  However, this approach proved to be technically 
challenging, and while some crystals were made, they were not of sufficient quality for 
resolution of the structure.  
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Figure 39.  IsaB Surface Association is Neutral Phosphatase 
Independent.  To determine if IsaB like Eap could bind to NPase an 
nPase deletion mutant was used.  S. aureus strains 10833, 10833ΔisaB, 
10833ΔnPase, and 10833ΔnPase+nPase were grown overnight in 
TSBG and supernatant and cell fractions were collected for western blot 
analysis.  No difference in IsaB cell surface association was observed 
between the wild-type and Npase mutant. 
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Figure 39.  IsaB Surface Association is Neutral Phosphatase 
Independent. 
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Modified Method for Expression and Purification of IsaB. 
As discussed earlier, we had previous success with cloning and purifying 
recombinant pre-IsaB using a C-terminal CBD tag.  However we required increased yield, 
purity, and production of mature IsaB lacking the signal sequence (m-IsaB). We cloned m-
isaB into a modified pET vector (pET32XT) that contained an N-terminal thioredoxin tag 
immediately followed with a his-tag and thrombin cleavage site. A detailed schematic of 
the expression and purification steps is outlined in Figure 40. (m-IsaB for these studies 
was expressed in LB; m-IsaB for NMR was grown in M9 minimal media with N and C 
isotopes).  As shown on the SDS Page in Figure 40, highly purified IsaB was obtained. 
 
m-IsaB Binds DNA. 
 In order to confirm that removal of the signal peptide did not interfere with the 
nucleic acid-binding activity, we repeated the EMSA assay with m-IsaB. The DNA probe 
was labeled with biotin, and detected with strepavidin-HRP.  As shown in Figure 41, m-
IsaB is still capable of binding and shifting DNA in an m-IsaB concentration dependent 
manner.   
 We also wanted to determine whether or not IsaB might have nuclease activity or 
modify the DNA probe in any way.  Reactions were setup as for a normal EMSA, however 
following 30 minutes incubation at room-temperature the reactions were electrophoresed 
under denaturing conditions on a TBE-Urea gel. Because m-IsaB is known to be expressed 
in acidic conditions and could be active at lower pH, one set of reactions were performed 
in binding-buffer at pH 5.8.  The results of this experiment are shown in Figure 42.  
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Figure 40.  Overview of Expression and Purification.  Schematic 
illustrating the methods used to purify recombinant m-IsaB.  For activity 
and binding assays, m-IsaB was expressed in LB while protein purified 
for NMR purposes was grown in M9 supplemented with the indicated 
isotopes for incorporation into the protein. 
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Figure 40.  Overview of Expression and Purification. 
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Figure 41.  m-IsaB Still Binds DNA.  To ensure that purified 
recombinant m-IsaB still retained its Nucleic acid binding activity 
EMSAs were performed.  All reactions contained 1fmol biotinylated 
DNA probe. Lane 1, no IsaB control, Lane 2, 1.6 nmol IsaB, Lane 3, 160 
pmol IsaB, Lane 4,  16 pmol IsaB, Lane 5, 160 fmol IsaB.  m-IsaB was 
able to shift the ssDNA probe in a concentration dependent manner. 
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Figure 41.  m-IsaB Still Binds DNA. 
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Figure 42.  IsaB Does Not Modify DNA.  To observe if m-IsaB has any 
activity on bound DNA EMSA reactions were set up with normal or 
decreased pH and ran under denaturing conditions to break up the 
probe/m-IsaB complex.  EMSA reactions were used at “normal” 7.6pH or 
were buffered with pH 5.8 phosphate buffer.  Each pH had a complete set 
of reactions.  Lane 1, no m-IsaB control, Lane 2, 1.6 nmol m-IsaB, Lane 
3, 160 pmol IsaB.  Reactions were denatured with heat and 
electrophoresed through a denaturing TBE-Urea gel.  No modification of 
the probe nor decrease in signal intensity was observed. 
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Figure 42.  IsaB Does Not Modify DNA. 
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From this blot it does not appear that m-IsaB is degrading or modifying the ssDNA in 
either of the reactions at pH 7.6 or 5.8.  The signals at the top of the blot in the lanes with 
the greatest amount of m-IsaB are presumably aggregates of protein/DNA that were unable 
to migrate through the gel due to the high protein concentration.   
 
LTA Does Not Compete with m-IsaB Binding DNA. 
 As mentioned previously, teichoic acids come in two varieties, LTA and WTA, 
both of which are very negatively charged.  As discussed above, we found that WTA is not 
responsible for IsaBs binding to the cell surface.  However, it had previously been 
observed that IsaBs nucleic acid binding could be successfully out competed with S. 
aureus cell membrane extracts (personal communication Dr. Kimberly Jefferson).  To 
determine if the cell extract competition was due to LTA, competitive EMSAs were 
performed using LTA in great excess over the labeled probe.  As shown in Figure 43,  
LTA was unable to successfully out compete binding of IsaB to the labeled probe.  Again 
suggesting that IsaB is not significantly interacting with teichoic acids. 
 
Drum-roll Please….and the Structure is… 
 In order to use NMR for structural determination of m-IsaB we needed to purify a 
large amount of labeled m-IsaB in solution that would not aggregate, and contained only a 
single species.  For expression, cultures were serially grown in minimal M9 media in 
which the only sources of nitrogen and carbon were the 15NH4Cl and 13C-glucose isotopes.  
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Figure 43.  LTA Does Not Compete With DNA for Binding. To 
visualize if lipoteichoic acid could ablate the DNA shift a competitive 
EMSA was performed where unlabeled teichoic acid at varying 
concentrations was added to the reactions.  Each reaction contained 1 
fmol probe, 160 pmol m-IsaB.  Lane 1, no m-IsaB control, Lane 2, 
EMSA control, Lane 3, EMSA + 1 ug LTA, Lane 4, EMSA + 100 ng 
LTA, and Lane 5, EMSA + 10 ng LTA.  No significant competition of 
IsaB binding was observed at any concentrations of LTA. 
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Figure 43.  LTA Does Not Compete With DNA for Binding. 
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Growth in this media was necessary to ensure that these atoms were used in the building of 
amino acids and subsequently in protein production.  Using the purification process shown 
in Figure 40, we were able to successfully purify m-IsaB which appeared to be single 
species, to a concentration of ~1M without any aggregation being observed, which 
evidently is much more then needed for NMR.  At this point the protein sample was turned 
over to Dr. David Williams for determination of structure.  Figure 44 illustrates the 
progress that has been made in determining the structure of IsaB.  Figure 44a/b includes 
TALOS software predictions based on the assigned residues from the 15N-HSQC plot that 
is shown in Figure 44c [152].  From these data it appears that IsaB contains multiple β-
sheets and at least two extended α-helices (Figure 44b).  Furthermore the predictions 
suggest that IsaB is highly structured with only a small region predicted to be un-ordered 
(Figure 44a).  However, these studies are currently in progress and determination of the 
structure of IsaB will by completed by the end of April 2010. 
 
Discussion: 
The studies presented in this chapter were aimed at characterizing the structure of 
mature IsaB.  To begin we were intrigued by the lack of a predicted LPXTG motif and the 
ability of IsaB to associate with the bacterial cell surface.  Using a Sortase A deficient 
mutant, we found that IsaB is a true anchorless protein, as its association with the cell 
surface is not dependent upon the Sortase A activity of covalently linking proteins to the 
cell wall.  While these results are interesting, they are not entirely novel as other proteins in  
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Figure 44. Nuclear Magnetic Resonance.  Currently determinantion of 
the structure of IsaB is currently underway.  However a large amount of 
data has been collected thus far allowing for highly accurate predictions 
to be formed with the TALOs software (95% accuracy).  a)  Readout 
from TALOs demonstrating the predicted ordered regions of protein 
structure.  Only one area from ~95 to 100 aa appear to be unordered as 
shown by the dip in the chart.  b)  Secondary structure prediction from 
TALOs, lines above the axis indicate β-sheets while lines below are 
α-helices.  IsaB appears to have two extended α-helices and several 
regions of β-sheets.  c)  15N-HSQC, shows the resonance of all labeled N 
throughout the protein in 2D. 
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Figure 44. Nuclear Magnetic Resonance. 
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S. aureus and other Gram-positives exhibit similar non-covalent cell wall binding 
characteristics.  Motivated by reports of how two anchorless proteins associate with the 
cell surface, we determined that neither WTA nor NPase were responsible for the 
rebinding of IsaB.  The western blot on the WTA deficient strain could not rule out the 
potential that the cytoplasmic membrane tethered LTA was responsible for IsaB cell 
surface association and this scenario cannot be completely ruled out without testing a LTA 
deficient strain.  
Another interesting observation made with the Sortase A deficient mutant was that 
no visible decrease was seen in the strength of the IsaB signal.  This finding is significant 
because without Sortase A, cell-wall anchored proteins are released into the extracellular 
milieu and are not associated with the cell wall.   This indicates that IsaB is interacting 
with a protein(s) or other substance that is not covalently linked by an LPXTG motif, 
which drastically decreases the number of binding suspects.  It is also entirely possible that 
IsaB is interacting with the surface simply through charge attractions as the overall cell 
surface of S. aureus is negatively charged and IsaB is highly cationic.  While these studies 
were interesting, they reveal little about the activity or structure of IsaB, therefore we 
focused on obtaining structural analysis of IsaB. 
We first attempted to obtain crystal structure of IsaB through a collaboration with 
Drs. Martin Safo and Faik Musayev but this was not successful. One of the technical 
problems was related to degradation products that prevented crystal formation.  As 
discussed in Chapter 3, IsaB was predicted to have an N-terminal signal peptide sequence 
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for secretion, and in support of this, we found IsaB to be secreted and surface-associated.  
Importantly, the recombinant IsaB we were using for crystallography still contained the 
majority of the signal peptide sequence, which led us to hypothesize that the degradation 
product interfering with crystal formation had lost its signal peptide sequence.  We needed 
to remove the signal peptide sequence to obtain the structure of the protein, and also to 
determine if removal of signal peptide sequence was required for activation of and 
potential enzymatic function of IsaB. 
Protein activities are typically determined using recombinant purified protein of 
interest so that the function, which may not have a large phenotype under most conditions, 
can be elucidated.  Using a number of purification strategies and a large amount of trial 
and error we finally found a system that expressed large amounts of m-IsaB.  Through our 
numerous trials we believe that a large N-terminal tag was required for successful 
expression of IsaB, which we hypothesize was able to block m-IsaBs toxic activity inside 
of E. coli.  Upon successful purification of m-IsaB we found that it, like pre-IsaB binds to 
ssDNA in a concentration dependent manner.  Using denaturing Urea gels, we found that 
also like pre-IsaB, m-IsaB had no apparent role in modifying the DNA in the reactions.  
While these experiments are positive reinforcement of what we previously found 
with pre-IsaB, the main goal of expressing and purifying recombinant m-IsaB was to use it 
for NMR to determine its protein structure.  While we have shown that IsaB protects S. 
aureus against AMPs and can bind to eDNA, it was still unknown what its structure was.  
Currently Dr. David Williams is employing his NMR expertise to determine the structure 
of IsaB, and it is estimated that these studies will be successfully completed by the end of 
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April 2010.  Once the structure is obtained, it will be used to search for homology to other 
solved protein structures, which will help us to assign IsaB to a functional class. 
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CHAPTER 8 
Conclusions 
 
 
When our studies first began, the only known property of IsaB was its 
immunogenicity. It was postulated to be involved in virulence but as this protein bears no 
homology to other proteins of known function and had never been studied, this claim was 
purely speculative.  Our lab first became interested in IsaB following a screen performed in 
search of RNA binding proteins able to post-transcriptionally regulate the intercellular 
adhesin (ica) locus, a locus that is responsible for production of PNAG.  While multiple 
experiments determined that IsaB does not regulate ica expression or PNAG production, 
we were still intrigued by this uncharacterized protein.  As discussed earlier, IsaB does not 
have any significant similarity to proteins of known function and therefore we could gain 
no insight into its function.   
Adding to the level of mystery about IsaB is the fact that it is found in all S. aureus 
strains sequenced, and has homologs in all Staphylococcal species currently annotated.  
However, IsaB homologs have not been found in other annotated genomes outside this 
genus.  These results taken together suggest an important role for IsaB due to its 
widespread occurrence throughout a genus with great genetic diversity.  One could argue 
that this prevalence among staphylococci makes IsaB an unlikely virulence factor, as 
widespread genes are usually involved in housekeeping.  While this is a strong argument, it 
is prudent to note that staphylococci are typically found associated with higher hosts, 
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which could be indicative of a role in virulence as all Staphylococcal species are 
challenged by host immune defenses.  Therefore it is highly possible that IsaB, which is 
known to be immunogenic during human septicemia caused by S. aureus, could be not 
only an important virulence factor in S. aureus but also in other staphylococcal species 
which cause disease in a wide range of vertebrate hosts.  Therefore characterization of this 
protein could lead to therapeutic interventions in both human and veterinary settings alike.   
 
Regulation of IsaB 
As nothing was known about IsaB, we first began our characterization of the isaB 
gene by characterizing its regulatory network, in the hope that this would shed light on 
possible roles in virulence and function.  Perhaps the most potent regulator of isaB 
expression we observed was acidic pH, however it took numerous different experiments to 
determine this.  In the beginning we found that isaB expression was dramatically induced 
by easily metabolized sugars such as glucose, and therefore hypothesized that isaB was 
one of many genes being regulated by glucose.  These studies prompted us to examine the 
role that CcpA had on isaB expression, and as we hoped we found that CcpA was a 
positive regulator of isaB.  While this made for a nice story, there was a red flag.  
Maximum isaB transcript levels were observed in post-exponential phase, when all easily 
metabolized glucose should be gone.  We therefore needed to look into other possible 
factors that would be occurring in a time-dependent manner starting after glycolysis had 
initiated.   
   
 174 
As aerobic bacteria in culture grow, CO2 and acetic acid accumulate in the media, 
which leads to a decrease in the pH from ~7.5 to ~4.5 over only a few hours.  We 
speculated that acidic conditions were actually behind the induction of isaB.  Because S. 
aureus grown in acidic media exhibit a significant delay in growth, to address this question 
we used HEPES buffer to significantly delay acidification of the media.  In support of our 
hypothesis, we found that once the media was buffered and the drop in pH delayed, much 
of the induction by glucose was ablated.  Another interesting finding was that the pattern 
of isaB induction of cultures grown in the buffered media was strikingly similar to what 
was observed for the CcpA mutant.  By repeating the CcpA time-course and monitoring 
the change in pH we found that the CcpA mutation was associated with a  significant delay 
in the acidification of the media.  Therefore, we were able to conclude that pH, not glucose 
or CcpA was responsible for the majority of the isaB induction. 
As IsaB has been found to be immunogenic during MRSA septicemia we wanted to 
determine the effect that culture in whole serum or plasma had on isaB expression levels.  
As we hypothesized, isaB expression was increased approximately 5-fold following two 
hours of culture in either serum or plasma.  While there are many components in either 
fluid which could be stimulating isaB expression (antibodies, complement, hormones, etc) 
it is unlikely that clotting factors such as platelets, which are present in plasma and not 
serum, are responsible for the increase.  These data support our overall hypothesis that 
IsaB is expressed during septicemia and is important in the pathogenesis of S. aureus. 
Another significant piece of information obtained about isaB regulation was the 
finding that SarA negatively regulates isaB expression. SarA is a known regulator of 
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secreted proteins and regulates genes in a temporal fashion, so this finding was not 
unexpected. SarA is also an important regulator of virulence determinants, so its role in 
isaB expression supported our hypothesis that IsaB is involved in virulence. 
 
IsaB Binds Nucleic Acids 
 Prior to beginning this project, we had strong reason to believe that IsaB was able 
to bind to RNA, as it was the only protein which was previously isolated in an RNA 
affinity chromatography assay.  Due to IsaB being fully secreted and not covalently 
anchored to the cell wall, the idea of an extracellular RNA binding protein was exciting 
and novel as the only other secreted protein known to bind nucleic acids in S. aureus is the 
Thermostable nuclease.  Using recombinant purified full-length IsaB from a previously 
constructed E. coli strain, we first sought to visualize IsaB binding through EMSAs.  
Through a number of these experiments we determined that not only did IsaB bind RNA, it 
also bound to DNA.  Furthermore, it appeared as though IsaB binding was occurring in a 
non-sequence specific manner because non-specific carrier DNA used in the gel shifts was 
able to out-compete the labeled probe for IsaB binding.   
 While the EMSAs allowed for direct observation of IsaB binding to nucleic acids, 
they did not tell us much about the affinity IsaB had for these ligands.  In order to 
determine dissociation/association constants we used Surface Plasmon Resonance (SPR).  
Using biotinylated RNA, ss-DNA, or ds-DNA oligos as bait, and varying concentrations of 
IsaB we were able to determine that IsaB binds to the tested oligos in the low nM range.  
Interestingly, this binding affinity is very similar to the affinities of transcriptional 
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regulators when they are bound to heterologous DNA.  While unlikely, due to its 
extracellular nature, it is possible that IsaB may recognize a specific sequence that we have 
not yet identified.  To address this in the future, assays such as selex could be used to 
determine if there is a sequence IsaB preferentially binds to.  Furthermore, we found that 
endogenously expressed IsaB can aid in the accumulation of eDNA on the cell surface, 
supporting and lending relevance to our in vitro studies.   
 An extracellular nucleic acid binding protein could have many functions in S. 
aureus. IsaB binding nucleic acid could potentially block activation of TLR-9 which 
recognizes bacterial unmethylated CpG DNA leading to NfΚb signaling and amplification 
of the immune response.  Along these lines of thought, it would be interesting to determine 
affinity of IsaB for bacterial DNA or Human DNA, to see if IsaB could bind with higher 
affinity to unmethylated vs. methylated CpG DNA. 
 
IsaB as a Virulence Factor 
IsaB is immunogenic and expressed in vivo where it is actively targeted by the 
adaptive immune response. Why would S. aureus produce a protein in vivo that would 
serve as a target for host immune defenses? We hypothesized that IsaB was expressed in 
vivo, despite its immunogenicity, because it plays a critical role in the virulence of S. 
aureus. To test this we used a number of different assays to observe IsaBs role in 
virulence.  We used assays ranging in complexity from single molecule killing assays 
(AMPs), neutrophil mediated killing (phagocytosis and NETs), adherence and intracellular 
survival, survival in whole blood, to the C. elegans nematode killing model. 
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Through these assays we found that IsaB has a significant role in protecting S. 
aureus from Antimicrobial Peptides and Neutrophil Extracellular Traps.  We hypothesize 
that IsaB protects against AMPs, which subsequently gives S. aureus increased resistance 
to NETs, whose killing mechanism relies heavily on AMPs.  These findings suggest that 
IsaB is a novel virulence factor that increases S. aureus survival in vivo and in turn can 
lead to more severe disease.  Furthermore, the ability of IsaB to protect against AMPs 
makes it relevant to all S. aureus diseases, as AMPs are part of the innate immune system 
secreted throughout the body.  While at this time we do not know conclusively how IsaB 
protects against AMPs, it is highly likely that it is through repulsive forces.  S. aureus goes 
through great lengths to modify its cell surface to change its overall charge from negative 
to neutral to prevent the cationic AMPs binding.  Therefore we hypothesize that IsaB helps 
modify the surface charge, preventing AMPs from binding to the cell wall.  These findings 
warrant further study to elucidate this mechanism. 
As discussed above, AMPs are highly conserved throughout all animals, from 
nematodes to humans, and IsaB is conserved throughout the staphylococci.  These two 
pieces taken together suggest that IsaB evolved early in the Staphylococcal genus and 
could have significant roles in AMP evasion in all staphylococci that are associated with 
higher organisms.  Therefore this is an exciting finding as IsaB has implications in human 
disease but could also be relevant to veterinary diseases caused by staphylococci, making 
IsaB an exceptionally attractive therapeutic target. 
 
 
   
 178 
Biofilms 
 Recent studies by Dr. Bayles laboratory (University of Nebraska), have 
demonstrated that S. aureus biofilms can have an abundance of eDNA within their matrix.  
While this phenomenon has been established in many other bacterial biofilms, it was only 
recently confirmed for S. aureus biofilms, which were previously thought to primarily 
consist of PNAG.  Given the novelty of eDNA in biofilms, and our possession/knowledge 
of a novel extracellular nucleic acid binding protein we were excited to determine how 
IsaB affected biofilm formation.  We hypothesized that deletion of IsaB would decrease 
the overall biofilm formed due to a significant decrease in the amount of eDNA that was 
incorporated into the biofilm matrix.   
 Using the well-established 96 well biofilm microtiter plate assay we screened wild-
type and isaB deletion mutants in a variety of growth media with different supplements.  
Under most conditions we found no difference in the amount of biofilm formed in the 
presence or absence of IsaB.  However, in the conditions where a significant change was 
observed between the deletion mutant and wild-type, it was the deletion mutant which had 
slightly greater levels of biofilm formation.  Therefore, under certain inducing conditions, 
IsaB seemed to negatively affect biofilm formation, although this effect was minor.  
However this negative role does not seem to be due the amount of eDNA in the biofilm as 
DNAse susceptibility assays suggest that similar amounts of eDNA were in the biofilms of 
two strains.  We also hypothesized that we were perhaps not stimulating IsaB expression 
appropriately, and since isaB is expressed in serum, we performed the biofilm assays in the 
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presence of serum, and again found no significant difference between the wild-type and 
deletion.   
 These findings suggest that IsaB plays little, if any role in biofilm formation.  The 
increase observed in the mutant was only 12%, and while it was statistically significant, we 
are unable to comment on whether this is a physiologically relevant increase.  One way to 
explain the observed increase in biofilm formation is that perhaps IsaB binding to eDNA 
blocks it from being properly incorporated into the biofilm and is acting as a mechanism to 
fine tune biofilm formation.  However it is still be possible that IsaB plays a role in 
augmenting biofilm formation under conditions not addressed, or in S. aureus strains not 
used in these studies. 
 
Structure of IsaB 
 As indicated by results in Chapter 3, IsaB was only found in extracellular fractions 
of S. aureus cultures wherein a minor fraction was present in the spent medium and the 
majority was associated with the cell surface.  This was intriguing because IsaB is an 
“anchorless” protein, having no predicted cell-wall anchoring motif.  Furthermore, using a 
Sortase A deletion mutant we confirmed that IsaB cell surface association is independent 
of Sortase A, and thus is not covalently linked to the cell-wall.  While this is an interesting 
finding, it is not an entirely rare occurrence as other S. aureus proteins that are fully 
secreted such as Eap and NPase are able to “re-bind” the cell surface.  This re-binding can 
occur through binding to other cell-surface associated proteins, and also by binding to LTA 
or WTA.  Using deletion mutants of both NPase and WTA, we concluded that IsaBs cell-
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surface association is independent of these two factors.  Therefore it is still unknown how 
IsaB is interacting with the cell surface.    
Our initial studies used recombinant IsaB purified from E. coli containing an 
expression vector with the entire isaB open reading frame. IsaB is an extracellular protein, 
and upon examination of its amino acid sequence with SignalP 3.0 we were able to predict 
where its signal peptide would be cleaved once secreted.  An important paradigm found for 
many secreted proteins is that the protein must be processed after secretion to become 
active.  This mechanism is likely used to protect the intracellular components of an active 
enzyme that could potentially harm the bacteria producing it.  Because of this phenomenon 
we predicted that we had not detected enzymatic activity of our previously produced 
recombinant protein because this construct included the Gram-positive signal peptide 
sequence, which would not be appropriately processed in the Gram-negative E. coli.  
Furthermore, in order to determine the structure of mature IsaB, the signal peptide 
sequence would need to be removed, and therefore we began experiments to express and 
purify large amounts of m-IsaB.  
After a myriad of different techniques and cloning strategies we were finally able to 
express the mature, secreted form of IsaB (m-IsaB) in E. coli.  In our successful approach a 
large N-terminal tag encoding thioredoxin, 6-his, and a thrombin cleavage site, was fused 
immediately prior to the start of the 5’ end of m-IsaB, therefore purified protein would not 
have a signal peptide sequence on it. Once large amounts of highly pure m-IsaB were 
obtained we repeated a number of our EMSAs.  These EMSAs showed that m-IsaB is still 
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capable of binding DNA in an IsaB concentration dependent manner, however no 
enzymatic activity on DNA was observed. 
Our main motivation behind producing m-IsaB was to use it for structural analysis 
through NMR, which was performed by our collaborators with significant experience.  
These studies are currently in progress and should be concluded shortly.  By obtaining the 
structure of IsaB we hope to find clues as to how IsaB is interacting with either eDNA or 
AMPs.  Furthermore, we can then search for structural homologs to determine if IsaB 
could in fact have another function in S. aureus. 
In summary, these studies have determined that IsaB is an extracellular DNA 
binding protein that significantly protects the bacteria from AMPs and NETs.  These 
findings demonstrate that IsaB is an important virulence factor in S. aureus and possibly in 
other staphylococci.  Furthermore, our experiments have shown that isaB expression is 
regulated by a complex network including the global regulator SarA and a number of 
environmental stimuli including serum/plasma components and pH.  These studies 
illustrate that IsaB is a clinically relevant virulence factor, with potential therapeutic 
implications.  It will be exciting to observe how the story of the Immunodominant Surface 
Antigen B progresses and develops from these initial studies. 
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